WO2021045237A1 - Packaging body for tablet containing trichloroisocyanuric acid - Google Patents
Packaging body for tablet containing trichloroisocyanuric acid Download PDFInfo
- Publication number
- WO2021045237A1 WO2021045237A1 PCT/JP2020/033842 JP2020033842W WO2021045237A1 WO 2021045237 A1 WO2021045237 A1 WO 2021045237A1 JP 2020033842 W JP2020033842 W JP 2020033842W WO 2021045237 A1 WO2021045237 A1 WO 2021045237A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- layer
- tcca
- package
- tablet
- tablets
- Prior art date
Links
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 title claims abstract description 140
- 238000004806 packaging method and process Methods 0.000 title claims abstract description 18
- 229950009390 symclosene Drugs 0.000 title claims description 26
- -1 polyethylene terephthalate Polymers 0.000 claims abstract description 48
- 229910052751 metal Inorganic materials 0.000 claims abstract description 28
- 239000002184 metal Substances 0.000 claims abstract description 28
- 239000011347 resin Substances 0.000 claims abstract description 24
- 229920005989 resin Polymers 0.000 claims abstract description 24
- 239000004698 Polyethylene Substances 0.000 claims abstract description 20
- 229920000573 polyethylene Polymers 0.000 claims abstract description 20
- 229920000139 polyethylene terephthalate Polymers 0.000 claims abstract description 19
- 239000005020 polyethylene terephthalate Substances 0.000 claims abstract description 19
- 238000003466 welding Methods 0.000 claims abstract description 9
- 229910052782 aluminium Inorganic materials 0.000 claims description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 8
- 239000004743 Polypropylene Substances 0.000 claims description 7
- 229920001155 polypropylene Polymers 0.000 claims description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 6
- 229920000554 ionomer Polymers 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 4
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 4
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 abstract description 114
- 238000003860 storage Methods 0.000 abstract description 25
- 238000000354 decomposition reaction Methods 0.000 abstract description 14
- 238000007789 sealing Methods 0.000 abstract description 4
- 238000004321 preservation Methods 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 19
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 14
- 230000002378 acidificating effect Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000001877 deodorizing effect Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004332 deodorization Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 101150032799 PE15 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical class N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229910003437 indium oxide Inorganic materials 0.000 description 1
- PJXISJQVUVHSOJ-UHFFFAOYSA-N indium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[In+3].[In+3] PJXISJQVUVHSOJ-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
- A01N43/66—1,3,5-Triazines, not hydrogenated and not substituted at the ring nitrogen atoms
- A01N43/68—1,3,5-Triazines, not hydrogenated and not substituted at the ring nitrogen atoms with two or three nitrogen atoms directly attached to ring carbon atoms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/36—Layered products comprising a layer of synthetic resin comprising polyesters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
- B65D65/38—Packaging materials of special type or form
- B65D65/40—Applications of laminates for particular packaging purposes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
Definitions
- the present invention is also referred to as a tablet containing trichloroisocyanuric acid (hereinafter, also referred to as "TCCA”), which is dissolved in water at the time of use and sprayed indoors to be used for sterilization and deodorization (hereinafter, also referred to as "TCCA-containing tablet”). ) Is related to the packaging body.
- TCCA trichloroisocyanuric acid
- hypochlorous acid water aqueous solution of hypochlorous acid
- hypochlorous acid dissolved in water has been used. It has the disadvantage that sterilizing and deodorizing components such as chloric acid volatilize.
- hypochlorous acid water is sold in bottles and packs, but since the sterilizing and deodorizing components such as hypochlorous acid volatilize, it is sold and used in a short period of time after it is manufactured. It is necessary and troublesome to handle.
- Patent Document 1 states that a liquid having a bactericidal action and a deodorizing action is stored in a water storage unit, and this liquid is sprayed to remove the room.
- Bacteria and deodorization are disclosed, and Patent Documents 2 and 3 contain electrolyzed water containing hypochlorous acid and active oxygen, which have bactericidal and deodorizing effects by electrolyzing water such as tap water. It is disclosed that the electrolyzed water is sprayed to sterilize and deodorize the room.
- Patent Documents 4 and 5 disclose that TCCA-containing tablets are used as a cleaning agent for removing slime from a drain port.
- Patent Document 1 it takes time and effort to prepare a special liquid having a bactericidal action and a deodorizing action, and when a commercially available hypochlorous acid water is used, the above-mentioned It becomes troublesome to handle. Further, in Patent Documents 2 and 3, since a device for electrolyzing water such as tap water is required, cost and labor are required. The use of TCCA-containing tablets as a cleaning agent has been conventionally practiced as disclosed in Patent Documents 4 and 5, but has not been used to obtain hypochlorous acid water. ..
- Patent Document 6 Proposed a sterilization / deodorization system using TCCA-containing tablets (Patent Document 6) and further provided a blister package (Patent Document 7) in which a plurality of TCCA-containing tablets were packaged in a plastic package so as not to come into contact with each other.
- Patent Document 7 Proposed a sterilization / deodorization system using TCCA-containing tablets (Patent Document 6) and further provided a blister package (Patent Document 7) in which a plurality of TCCA-containing tablets were packaged in a plastic package so as not to come into contact with each other.
- a new problem with such packaging forms is the hydrolysis of TCCA itself due to moisture absorption, TCCA and alkali metal carbonates and / or bicarbonate alkalis that may be contained in TCCA tablets.
- Chlorine gas is generated by the reaction with the metal, and even if a package containing a metal layer is used to improve the gas barrier property, the metal is corroded and deteriorated by the slightly generated chlorine gas, and the gas barrier property is improved. The problem arises of rapid decline.
- TCCA-containing tablets decompose to generate chlorine during the storage / storage period (hereinafter, also referred to as “storage / storage period”) from the time they are manufactured / packaged to the time they are dissolved in water and used.
- storage / storage period also referred to as “storage / storage period”
- the present invention has been made by diligently studying a packaging capable of significantly reducing the decomposition of TCCA-containing tablets during the storage and storage period.
- an object of the package of the TCCA-containing tablet of the present invention is to significantly reduce the decomposition of the TCCA-containing tablet during the storage and storage period.
- TCCA-containing tablets a) A first layer composed of a polyethylene terephthalate layer, b) A third layer composed of an elastic resin layer laminated on the first layer, a second layer in which a metal layer and a polyethylene layer are arranged from the first layer side, and c) a second layer laminated on the second layer.
- the first layer is sandwiched by two laminated films having layers so as to face each other.
- the gist of the present invention is shown below.
- (1) Tablets containing trichloroisocyanuric acid a) A first layer composed of a polyethylene terephthalate layer, b) A third layer composed of an elastic resin layer laminated on the first layer, a second layer in which a metal layer and a polyethylene layer are arranged from the first layer side, and c) a second layer laminated on the second layer.
- the first layer is sandwiched by two laminated films having layers so as to face each other.
- a package of tablets containing trichloroisocyanuric acid which is sealed by welding the two laminated films to each other.
- the package of the TCCA-containing tablet of the present invention can significantly reduce the decomposition of the TCCA-containing tablet during the storage and storage period.
- TCCA-containing tablets ⁇ Ingredients of TCCA-containing tablets> TCCA-containing tablets contain TCCA as the main component.
- TCCA is a solid compound represented by the chemical formula of [Chemical formula 1], and when it is put into water, it releases active chlorine having a strong oxidizing ability similar to active oxygen, and makes water hypophilic. It can be chlorinated water.
- Hypochlorite water has a high bactericidal action against viruses and fungi, and can inactivate viruses such as norovirus and influenza virus, and fungi such as Staphylococcus aureus, anthrax, and salmonella. ..
- Hypochlorous acid is a very unstable substance and is known to gradually decompose in an aqueous solution, but TCCA has a solubility in water of about 1.2 g and a slow dissolution rate, so it can be dissolved in water. When charged, a low concentration of active halogen can be released over a long period of time.
- Hypochlorite water can be obtained easily and economically by putting TCCA-containing tablets into water, and further, by spraying this hypochlorite water, each household, hospital, nursery school, etc.
- the room can be easily and economically sterilized and deodorized.
- the TCCA-containing tablet may contain the following additives in addition to TCCA.
- bulking agents include alkali metal silicates, carbonates, bicarbonates, phosphates, sulfates, etc., in addition to sardines and salt.
- sardine is particularly preferable because it can contain water as water of crystallization and is useful as a moisture barrier, and alkali metal carbonates and / or bicarbonates contribute to the hydrolysis of TCCA and hypochlorous acid. It is particularly preferable because it causes the occurrence of.
- a binder or a lubricant can be contained in a proportion of about 0.1 to 5% by weight. By improving the moldability, it is possible to prevent the TCCA-containing tablet from being chipped or cracked, which occurs during the production or transportation of the TCCA-containing tablet.
- the binder has a function of binding solid particles and is preferably water-soluble, but is not particularly limited.
- the lubricant is not particularly limited as long as it has a function of improving the fluidity, filling property and adhesiveness of solid particles, and for example, calcium stearate, magnesium stearate, sodium stearate, sodium benzoate, orthoboric acid. , Talc, etc.
- persulfate, percarbonate or perborate can be contained as a foaming agent or a disintegrant.
- the foaming agent is composed of a combination of an acidic substance and an alkaline substance, and when the TCCA-containing tablet is put into water, both react to generate gas, so that the disintegration property of the TCCA-containing tablet can be enhanced.
- acidic substances include organic acids such as citric acid, tartaric acid, oxalic acid, succinic acid, maleic acid, phthalic acid, malic acid and adipic acid, sodium dihydrogen phosphate, potassium dihydrogen phosphate and ammonium dihydrogen phosphate.
- Hydrogen salts such as potassium hydrogen sulfate, and myobans such as carimyoban and ammonium myoban.
- alkaline substance include carbonates such as sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate and ammonium carbonate, and bicarbonates such as sodium bicarbonate and potassium bicarbonate.
- the disintegrant can absorb water and swell when the TCCA-containing tablet is put into water, or generate carbon dioxide gas and foam to disintegrate the TCCA-containing tablet.
- carboxymethyl cellulose calcium, crosslinked polyvinylpyrrolidone, and low degree of substitution. Hydroxypropyl cellulose and the like can be mentioned.
- the starch described above also functions as a binder, but also has a function as a disintegrant.
- TCCA-containing tablet in order to color or perfume the TCCA-containing tablet, conventionally known dyes, pigments or fragrances can be contained in the TCCA-containing tablet.
- a layer containing a dye, pigment or fragrance together with a bulking agent (excipient) is provided. It may be provided separately.
- TCCA-containing tablets are produced by a method of filling a mold with a raw material such as powder or granules of TCCA and pressurizing the mold (hereinafter, also referred to as "tablet").
- a known pressure-type locking machine composed of a mold (usuki) and a pressurizing device is preferably used.
- the raw materials are sequentially charged into the mortar and pressure is applied between the mortar and the pestle via a pressurizing device, the raw materials are crimped to produce a TCCA-containing tablet having a shape formed by the mortar and the pestle. Will be done.
- a single-shot tableting machine that locks one tablet at a time and a plurality of dies (molds) are mounted along a rotating disk, and the raw material is used during one rotation.
- a rotary tableting machine capable of continuously performing a series of operations such as filling, pressure molding, and taking out TCCA-containing tablets can be used.
- single-shot lockers include RIVA's "MINIPRESSM II” and "PICCOLA”, Kikusui Seisakusho's rigid powder molding machine, Okada Seiko's single-shot locker, and Fuji Yakuhin Kikai's standing press. Can be mentioned.
- rotary lockers examples include “Rotary Press TRP Series” manufactured by Mori Machinery Co., Ltd., “Clean Press Series” manufactured by Kikusui Seisakusho Co., Ltd., “Tough Press Series”, “P Series” manufactured by FETTE Co., Ltd., and “P Series”. Examples include “PT series”, “PH series” manufactured by KORSCH, and “B series” manufactured by Hata Iron Works.
- Hypochlorous acid water is strongly acidic hypochlorous acid water (pH 2.7 or less, effective chlorine concentration 20 to 60 ppm), weakly acidic hypochlorous acid water (pH 2.7 to 5.0, effective chlorine concentration 10 to 60 ppm). ), Slightly acidic hypochlorous acid water (pH 5.0 to 6.5, effective chlorine concentration 10 to 80 ppm), but the slightly acidic hypochlorous acid water has the same pH value as human skin. Because of the degree, it has a feature of being excellent in safety while having a high bactericidal action. In addition, it has the feature that the chlorine odor peculiar to chlorine-based bactericides does not remain.
- the weight of the TCCA-containing tablet is not particularly limited, but the range in which the water that fills the water tank of the device such as a spray, a spray device, a humidifier, etc. that sprays hypochlorite water can be made into slightly acidic hypochlorite water. It is preferable from the viewpoint of ease of use.
- a slightly acidic hypochloroisocyanuric acid water can be obtained by a simple operation of filling a water tank with water and putting one TCCA-containing tablet into the water tank.
- the pH is 5.5. Since slightly acidic hypochlorite water of up to 6.9 (depending on the alkalinity of tap water) can be obtained, the weight of the TCCA-containing tablet is preferably 0.3 to 1.0 g.
- the shape of the TCCA-containing tablet is not particularly limited, and the shape can be appropriately determined from the viewpoint of ease of tableting, ease of handling, and ease of use.
- Examples of the shape of the TCCA-containing tablet include a cylindrical shape, a cubic shape, a rectangular parallelepiped shape, and the like, but from the above viewpoint, the cylindrical shape is preferable.
- the diameter is 5 to 15 mm and the height is 2 to 6 mm.
- the laminated film (4) having the above is used.
- the TCCA-containing tablet (5) is sandwiched by the two laminated films (4) from above and below so that the first layer (1) faces each other.
- the two laminated films (4) that sandwich the TCCA-containing tablet (5) from above and below two separate laminated films may be used, or one laminated film may be folded back and used.
- a metal film is also used in the packaging of ordinary tablets in order to improve the gas barrier property.
- A is composed of an Aa layer made of a polyethylene terephthalate layer having excellent chemical resistance, heat welding resistance, etc., and an Ab layer made of a metal layer provided on the polyethylene terephthalate layer.
- a laminated film having a layer and a layer B composed of an elastic resin layer that protects the metal layer Ab is used.
- the TCCA-containing tablet of the present invention is hydrolyzed with a small amount of water to generate hypochlorous acid, which is decomposed into hydrogen chloride and free oxygen and corrodes the metal layer. Decomposition of TCCA is promoted during the storage / storage period.
- the polyethylene layer (2-1) of the second layer (2) in addition to the third layer (3) corresponding to the B layer, moisture permeates from the outside of the package and hydrogen chloride from the TCCA-containing tablet. Permeation can be significantly suppressed, and decomposition of TCCA-containing tablets during the storage and storage period can be significantly reduced.
- Example 1 As shown in Example 1 and Comparative Example 1 described later, surprisingly, by using a polyethylene layer (2-1) having a metal layer (2-2) as the second layer (2), Decomposition of TCCA-containing tablets during the storage / storage period can be significantly reduced.
- the package of the TCCA-containing tablet of the present invention is formed by sandwiching the TCCA-containing tablet from above and below with two laminated films so that the first layer faces each other, and sealing by welding the two laminated films.
- a laminated film (4) that has not been shaped in advance may be used as in the first embodiment shown in [FIG. 2], or TCCA as in the second embodiment shown in [FIG. 3].
- a laminated film (4) in which a portion corresponding to the accommodating portion of the contained tablet (5) is formed in a concave shape in advance may be used.
- TCCA-containing tablet of the present invention it is preferable that a plurality of TCCA-containing tablets are individually sealed by welding of a laminated film.
- the TCCA-containing tablet used in the packaging of the TCCA-containing tablet of the present invention contains anhydrous sodium sulfate.
- anhydrous sodium sulfate By containing anhydrous sodium sulfate in the TCCA-containing tablet, even if some water such as water vapor invades the sealed portion of the TCCA-containing tablet, the water can be fixed as water of crystallization by the anhydrous sodium sulfate, and decomposition of the TCCA-containing tablet is avoided. it can.
- the first layer (1) of the laminated film (4) is a basic material of the package of the present invention, and is mechanically and physically. It is formed using a polyethylene terephthalate layer (1-1) having excellent chemical properties.
- the polyethylene terephthalate layer (1-1) either an unstretched film or a stretched film stretched in the uniaxial direction or the biaxial direction can be used, but from the viewpoint of mechanical strength, the stretched film stretched in the biaxial direction can be used. It is preferable to use a film.
- the thickness of the polyethylene terephthalate layer (1-1) is preferably 5 to 25 ⁇ m, more preferably 10 to 20 ⁇ m.
- the thickness of the polyethylene terephthalate layer (1-1) is 5 ⁇ m or more, the permeation of water from the outside of the package and the permeation of hydrogen chloride from the TCCA-containing tablet can be reduced, and when it is 25 ⁇ m or less, the laminated film. Can be preferably welded.
- the second layer (2) of the laminated film (4) reduces the permeation of water from the outside of the package and the permeation of hydrogen chloride from the TCCA-containing tablet (5).
- a metal layer (2-2) and a polyethylene layer (2-1) are arranged from the first layer (1) side.
- a metal layer (2-2) and a polyethylene layer (2-1) are arranged from the first layer (1) side as an intermediate layer of the laminated film (4). It is possible to significantly suppress the permeation of water from the outside of the package and the permeation of hydrogen chloride from the TCCA-containing tablet, and significantly reduce the decomposition of the TCCA-containing tablet during the storage / storage period.
- a known method such as extrusion lamination or vapor deposition can be appropriately used.
- Examples of the metal used for the metal layer (2-2) include aluminum, silicon oxide, aluminum oxide, indium oxide, tin oxide, and zirconium oxide, but aluminum is preferable from the viewpoint of gas barrier property, corrosion resistance, versatility, and the like. ..
- the thickness of the metal layer (2-2) is preferably 1 to 20 ⁇ m, more preferably 5 to 10 ⁇ m. When the thickness of the metal layer (2-2) is 5 ⁇ m or more, the permeation of water from the outside of the package and the permeation of hydrogen chloride from the TCCA-containing tablet can be sufficiently reduced, and when the thickness is 20 ⁇ m or less, the strength becomes high. Sufficient moldability can be obtained without too much.
- polyethylene layer (2-1) either an unstretched film or a stretched film stretched in a uniaxial direction or a biaxial direction can be used, but from the viewpoint of mechanical strength, a stretched film stretched in the biaxial direction. Is preferably used.
- the thickness of the polyethylene layer (2-1) is preferably 5 to 25 ⁇ m, more preferably 10 to 20 ⁇ m. By setting the thickness of the polyethylene layer (2-1) to 5 to 25 ⁇ m, the metal layer (2-2) can be uniformly provided.
- the third layer (3) of the laminated film (4) is formed by using an elastic resin layer (3-1) to protect the second layer (2). Will be done.
- the resin used for the elastic resin layer (3-1) a resin having elasticity such as polypropylene, acrylic resin, ionomer resin and the like can be used, but polypropylene having excellent hardness and elasticity is preferable.
- the thickness of the elastic resin layer (3-1) may be any as long as it can properly fix and protect the metal layer (2-2), and varies depending on the resin used, but is generally preferably 20 to 50 ⁇ m. ..
- TCCA-containing tablets Using the above TCCA-containing tablets, a package of TCCA-containing tablets was prepared as in Examples 1 and 2 and Comparative Examples 1 and 2 below, and the following ⁇ stability test> was performed.
- Example 1 The following ⁇ first layer> to ⁇ third layer> were laminated and pressure-bonded to prepare a laminated film.
- First layer> Polyethylene terephthalate layer (15 ⁇ m)
- ⁇ Second layer> An aluminum layer (8 ⁇ m) and a polyethylene layer (15 ⁇ m) laminated on the first layer from the first layer side.
- ⁇ Third layer> A polypropylene layer (25 ⁇ m) laminated on the second layer.
- the laminated film is folded in half with the ⁇ first layer> on the inside, the TCCA-containing tablet is placed inside the folded film, the three sides in the open state are thermocompression-bonded, and the outside of the seam is cut out to cut out the TCCA-containing tablet of Example 1.
- a package of trichloroisocyanuric acid tablets was prepared.
- the laminated film is folded in half with the ⁇ first layer> on the inside, the TCCA-containing tablet is placed inside the folded film, the three sides in the open state are thermocompression-bonded, and the outside of the seam is cut out to cut out the TCCA-containing tablet of Comparative Example 1.
- a package of trichloroisocyanuric acid tablets was prepared.
- Example 2 In the packaging of Example 1, the TCCA-containing tablet of Example 2 was the same as in Example 1 except that the polypropylene layer (25 ⁇ m) of the ⁇ third layer> was changed to a layer (30 ⁇ m) formed of an ionomer resin. Ionomer packaging was created.
- Example 1 and Example 2 judged to be stable in the above ⁇ stability test> were dissolved in 5 L of tap water, they were immediately dissolved and the pH was 6.5.
- the concentration of hypochlorous acid was 200 ppm.
- the packaging of the TCCA-containing tablet of the present invention can significantly reduce the decomposition of the TCCA-containing tablet during the storage and storage period of the TCCA-containing tablet, and can stably reduce the decomposition of the TCCA-containing tablet at a predetermined concentration anytime and anywhere. It can be seen that ionized hypochlorous acid can be obtained.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Mechanical Engineering (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Composite Materials (AREA)
- Toxicology (AREA)
- Packages (AREA)
Abstract
The present invention addresses the problem, in a packaging body for a TCCA-containing tablet, of greatly reducing the decomposition of the TCCA-containing tablet during a preservation/storage period. A TCCA-containing tablet is sandwiched between two layered films each having (a) a first layer formed from a polyethylene terephthalate layer, (b) a second layer that is layered on the first layer and is such that a metal layer and a polyethylene layer are arranged in order from the first-layer side, and (c) a third layer that is layered on the second layer and is formed from an elastic resin layer, the TCCA-containing tablet being sandwiched so that the first layers face each other, and being packaged by sealing the two layered films through welding, thereby making it possible to greatly reduce decomposition of the TCCA-containing tablet during a preservation/storage period.
Description
本発明は、使用時に水に溶解し室内に噴霧して除菌・消臭に用いられる、トリクロロイソシアヌル酸（以下、「ＴＣＣＡ」ともいう。）を含有する錠剤（以下、「ＴＣＣＡ含有錠剤」ともいう。）を包装した包装体に関する。
The present invention is also referred to as a tablet containing trichloroisocyanuric acid (hereinafter, also referred to as "TCCA"), which is dissolved in water at the time of use and sprayed indoors to be used for sterilization and deodorization (hereinafter, also referred to as "TCCA-containing tablet"). ) Is related to the packaging body.
室内を除菌・消臭するために、これまで、各種イオン、オゾンを放出することが行われている。また、各種イオンで消臭できない匂いについては、活性炭を使った消臭フィルターを用いて消臭することも行われている。
In order to sterilize and deodorize the room, various ions and ozone have been released so far. In addition, odors that cannot be deodorized by various ions are also deodorized by using a deodorizing filter using activated carbon.
近年は、次亜塩素酸の水溶液（以下、「次亜塩素酸水」ともいう。）を噴霧して室内を除菌・消臭することが行われているが、水に溶けている次亜塩素酸等の除菌・消臭成分が揮発してしまうという欠点を有している。
In recent years, an aqueous solution of hypochlorous acid (hereinafter, also referred to as "hypochlorous acid water") has been sprayed to sterilize and deodorize the room, but hypochlorous acid dissolved in water has been used. It has the disadvantage that sterilizing and deodorizing components such as chloric acid volatilize.
このため、次亜塩素酸水はボトルやパックなどに詰めて販売されているが、次亜塩素酸等の除菌・消臭成分が揮発するため、製造してから短期間に販売・使用する必要があり取扱いが面倒である。
For this reason, hypochlorous acid water is sold in bottles and packs, but since the sterilizing and deodorizing components such as hypochlorous acid volatilize, it is sold and used in a short period of time after it is manufactured. It is necessary and troublesome to handle.
次亜塩素酸水を噴霧して室内を除菌・消臭することについて、特許文献１には、殺菌作用や脱臭作用を有する液体を貯水部に収容し、この液体を噴霧して室内を除菌・消臭することが開示されており、また、特許文献２および３には、水道水等の水を電気分解して殺菌作用や脱臭作用を有する次亜塩素酸や活性酸素を含む電解水を生成し、この電解水を噴霧して室内を除菌・消臭することが開示されている。また、特許文献４及び５には、排水口のヌメリ取り用洗浄剤として、ＴＣＣＡ含有錠剤を用いることが開示されている。
Regarding spraying hypochlorite water to sterilize and deodorize the room, Patent Document 1 states that a liquid having a bactericidal action and a deodorizing action is stored in a water storage unit, and this liquid is sprayed to remove the room. Bacteria and deodorization are disclosed, and Patent Documents 2 and 3 contain electrolyzed water containing hypochlorous acid and active oxygen, which have bactericidal and deodorizing effects by electrolyzing water such as tap water. It is disclosed that the electrolyzed water is sprayed to sterilize and deodorize the room. Further, Patent Documents 4 and 5 disclose that TCCA-containing tablets are used as a cleaning agent for removing slime from a drain port.
しかしながら、上記特許文献１では、殺菌作用や脱臭作用を有する専用の液体をわざわざ用意しなければならないため手間を要し、また、販売されている次亜塩素酸水を使用する場合には上記のように取扱いが面倒となる。また、上記特許文献２および３では、水道水等の水を電気分解するための装置が必要となるため、コスト、手間を要する。なお、ＴＣＣＡ含有錠剤を洗浄剤として利用することは、特許文献４及び５にも開示されているように、従来行われているが、次亜塩素酸水を得るために用いられてはいなかった。
However, in Patent Document 1, it takes time and effort to prepare a special liquid having a bactericidal action and a deodorizing action, and when a commercially available hypochlorous acid water is used, the above-mentioned It becomes troublesome to handle. Further, in Patent Documents 2 and 3, since a device for electrolyzing water such as tap water is required, cost and labor are required. The use of TCCA-containing tablets as a cleaning agent has been conventionally practiced as disclosed in Patent Documents 4 and 5, but has not been used to obtain hypochlorous acid water. ..
本発明者等は、各家庭、病院、保育所等の室内において、次亜塩素酸水の噴霧による室内の除菌、消臭を簡単かつ経済的に行えるようにすべく鋭意検討し、先に、ＴＣＣＡ含有錠剤を用いた殺菌・消臭システム（特許文献６）を提案し、さらに、ＴＣＣＡ含有錠剤を複数個、互いに接触しないようにプラスチック包装体で包装したブリスター包装体（特許文献７）を提案したところである。このような包装形態において問題として新たに上がってきたことは、吸湿により、ＴＣＣＡ自体の加水分解や、ＴＣＣＡと、ＴＣＣＡ錠剤に含有されることのあるアルカリ金属の炭酸塩および／または炭酸水素塩アルカリ金属との反応により塩素ガスを発生することであり、ガスバリア性を向上するために金属層を含む包装体を用いても、わずかに発生する塩素ガスによって、金属が腐食・劣化し、ガスバリア性が急速に低下するという問題が生じる。
The present inventors have diligently studied in order to make it easy and economical to disinfect and deodorize indoors by spraying hypochloroisocyanuric acid water in each home, hospital, nursery school, etc. , Proposed a sterilization / deodorization system using TCCA-containing tablets (Patent Document 6), and further provided a blister package (Patent Document 7) in which a plurality of TCCA-containing tablets were packaged in a plastic package so as not to come into contact with each other. I have just proposed. A new problem with such packaging forms is the hydrolysis of TCCA itself due to moisture absorption, TCCA and alkali metal carbonates and / or bicarbonate alkalis that may be contained in TCCA tablets. Chlorine gas is generated by the reaction with the metal, and even if a package containing a metal layer is used to improve the gas barrier property, the metal is corroded and deteriorated by the slightly generated chlorine gas, and the gas barrier property is improved. The problem arises of rapid decline.
上記のように、本発明者等は、ＴＣＣＡ含有錠剤を用いた殺菌・消臭システム（特許文献６）およびＴＣＣＡ含有錠剤をプラスチック包装体で包装したブリスター包装体（特許文献７）を提案したが、ＴＣＣＡ含有錠剤は、製造・包装されてから水に溶解して使用されるまでの保存・保管期間（以下、「保存・保管期間」ともいう。）において、分解して塩素を発生することから、保存・保管期間においてＴＣＣＡ含有錠剤の分解を大幅に低減できる包装について鋭意検討し、本発明を成したものである。
As described above, the present inventors have proposed a sterilization / deodorization system using TCCA-containing tablets (Patent Document 6) and a blister package (Patent Document 7) in which TCCA-containing tablets are packaged in a plastic package. , TCCA-containing tablets decompose to generate chlorine during the storage / storage period (hereinafter, also referred to as “storage / storage period”) from the time they are manufactured / packaged to the time they are dissolved in water and used. The present invention has been made by diligently studying a packaging capable of significantly reducing the decomposition of TCCA-containing tablets during the storage and storage period.
すなわち、本発明のＴＣＣＡ含有錠剤の包装体の課題は、保存・保管期間において、ＴＣＣＡ含有錠剤の分解を大幅に低減することにある。
That is, an object of the package of the TCCA-containing tablet of the present invention is to significantly reduce the decomposition of the TCCA-containing tablet during the storage and storage period.
ＴＣＣＡ含有錠剤を、
ａ）ポリエチレンテレフタレート層からなる第１層、
ｂ）上記第１層上に積層された、上記第１層側から金属層およびポリエチレン層を配した第２層、および
ｃ）上記第２層上に積層された、弾性樹脂層からなる第３層
を有する２枚の積層フィルムにより、上記第１層が対面するようにして挟持し、
上記２枚の積層フィルムの溶着により密封して包装することにより、保存・保管期間においてＴＣＣＡ含有錠剤の分解を大幅に低減することができる。 TCCA-containing tablets,
a) A first layer composed of a polyethylene terephthalate layer,
b) A third layer composed of an elastic resin layer laminated on the first layer, a second layer in which a metal layer and a polyethylene layer are arranged from the first layer side, and c) a second layer laminated on the second layer. The first layer is sandwiched by two laminated films having layers so as to face each other.
By sealing and packaging the two laminated films by welding, the decomposition of TCCA-containing tablets can be significantly reduced during the storage and storage period.
ａ）ポリエチレンテレフタレート層からなる第１層、
ｂ）上記第１層上に積層された、上記第１層側から金属層およびポリエチレン層を配した第２層、および
ｃ）上記第２層上に積層された、弾性樹脂層からなる第３層
を有する２枚の積層フィルムにより、上記第１層が対面するようにして挟持し、
上記２枚の積層フィルムの溶着により密封して包装することにより、保存・保管期間においてＴＣＣＡ含有錠剤の分解を大幅に低減することができる。 TCCA-containing tablets,
a) A first layer composed of a polyethylene terephthalate layer,
b) A third layer composed of an elastic resin layer laminated on the first layer, a second layer in which a metal layer and a polyethylene layer are arranged from the first layer side, and c) a second layer laminated on the second layer. The first layer is sandwiched by two laminated films having layers so as to face each other.
By sealing and packaging the two laminated films by welding, the decomposition of TCCA-containing tablets can be significantly reduced during the storage and storage period.
本発明の要旨を以下に示す。
（１）トリクロロイソシアヌル酸を含有する錠剤が、
ａ）ポリエチレンテレフタレート層からなる第１層、
ｂ）上記第１層上に積層された、上記第１層側から金属層およびポリエチレン層を配した第２層、および
ｃ）上記第２層上に積層された、弾性樹脂層からなる第３層
を有する２枚の積層フィルムにより、上記第１層が対面するようにして挟持され、
上記２枚の積層フィルム同士の溶着により密封されてなる、トリクロロイソシアヌル酸を含有する錠剤の包装体。
（２）上記錠剤が複数個存在し、該複数個の錠剤が、上記２枚の積層フィルムの溶着によりそれぞれ個別に密封されてなることを特徴とする、（１）に記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（３）上記錠剤が、さらに無水硫酸ナトリウムを含有することを特徴とする、（１）または（２）に記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（４）上記錠剤が、更にアルカリ金属の炭酸塩および／または炭酸水素塩を含有する（１）～（３）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（５）上記第１層の上記ポリエチレンテレフタレート層の厚さが５～２５μｍであることを特徴とする、（１）～（４）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（６）上記第２層の上記金属層の厚さが１～２０μｍであり、上記ポリエチレン層の厚さが１０～２０μｍであることを特徴とする、（１）～（５）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（７）上記金属層がアルミニウム層であることを特徴とする、（１）～（６）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（８）上記第３層の上記弾性樹脂層を形成する樹脂が、ポリプロピレン、アクリル系樹脂またはアイオノマー樹脂のいずれかであることを特徴とする、（１）～（７）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（９）上記第３層の上記弾性樹脂層の厚さが２０～５０μｍであることを特徴とする、（１）～（８）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The gist of the present invention is shown below.
(1) Tablets containing trichloroisocyanuric acid
a) A first layer composed of a polyethylene terephthalate layer,
b) A third layer composed of an elastic resin layer laminated on the first layer, a second layer in which a metal layer and a polyethylene layer are arranged from the first layer side, and c) a second layer laminated on the second layer. The first layer is sandwiched by two laminated films having layers so as to face each other.
A package of tablets containing trichloroisocyanuric acid, which is sealed by welding the two laminated films to each other.
(2) The trichloroisocyanuric acid according to (1), wherein a plurality of the tablets are present, and the plurality of tablets are individually sealed by welding the two laminated films. Package of tablets containing.
(3) The package of a tablet containing trichloroisocyanuric acid according to (1) or (2), wherein the tablet further contains anhydrous sodium sulfate.
(4) The package of the tablet containing the trichloroisocyanuric acid according to any one of (1) to (3), wherein the tablet further contains an alkali metal carbonate and / or a hydrogen carbonate.
(5) The package of a tablet containing trichloroisocyanuric acid according to any one of (1) to (4), wherein the polyethylene terephthalate layer of the first layer has a thickness of 5 to 25 μm. ..
(6) Any of (1) to (5), wherein the thickness of the metal layer of the second layer is 1 to 20 μm, and the thickness of the polyethylene layer is 10 to 20 μm. A package of tablets containing the above-mentioned trichloroisocyanuric acid.
(7) The package of a tablet containing trichloroisocyanuric acid according to any one of (1) to (6), wherein the metal layer is an aluminum layer.
(8) The method according to any one of (1) to (7), wherein the resin forming the elastic resin layer of the third layer is either polypropylene, acrylic resin or ionomer resin. Package of tablets containing trichloroisocyanuric acid.
(9) The package of a tablet containing trichloroisocyanuric acid according to any one of (1) to (8), wherein the elastic resin layer of the third layer has a thickness of 20 to 50 μm. ..
（１）トリクロロイソシアヌル酸を含有する錠剤が、
ａ）ポリエチレンテレフタレート層からなる第１層、
ｂ）上記第１層上に積層された、上記第１層側から金属層およびポリエチレン層を配した第２層、および
ｃ）上記第２層上に積層された、弾性樹脂層からなる第３層
を有する２枚の積層フィルムにより、上記第１層が対面するようにして挟持され、
上記２枚の積層フィルム同士の溶着により密封されてなる、トリクロロイソシアヌル酸を含有する錠剤の包装体。
（２）上記錠剤が複数個存在し、該複数個の錠剤が、上記２枚の積層フィルムの溶着によりそれぞれ個別に密封されてなることを特徴とする、（１）に記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（３）上記錠剤が、さらに無水硫酸ナトリウムを含有することを特徴とする、（１）または（２）に記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（４）上記錠剤が、更にアルカリ金属の炭酸塩および／または炭酸水素塩を含有する（１）～（３）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（５）上記第１層の上記ポリエチレンテレフタレート層の厚さが５～２５μｍであることを特徴とする、（１）～（４）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（６）上記第２層の上記金属層の厚さが１～２０μｍであり、上記ポリエチレン層の厚さが１０～２０μｍであることを特徴とする、（１）～（５）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（７）上記金属層がアルミニウム層であることを特徴とする、（１）～（６）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（８）上記第３層の上記弾性樹脂層を形成する樹脂が、ポリプロピレン、アクリル系樹脂またはアイオノマー樹脂のいずれかであることを特徴とする、（１）～（７）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。
（９）上記第３層の上記弾性樹脂層の厚さが２０～５０μｍであることを特徴とする、（１）～（８）のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The gist of the present invention is shown below.
(1) Tablets containing trichloroisocyanuric acid
a) A first layer composed of a polyethylene terephthalate layer,
b) A third layer composed of an elastic resin layer laminated on the first layer, a second layer in which a metal layer and a polyethylene layer are arranged from the first layer side, and c) a second layer laminated on the second layer. The first layer is sandwiched by two laminated films having layers so as to face each other.
A package of tablets containing trichloroisocyanuric acid, which is sealed by welding the two laminated films to each other.
(2) The trichloroisocyanuric acid according to (1), wherein a plurality of the tablets are present, and the plurality of tablets are individually sealed by welding the two laminated films. Package of tablets containing.
(3) The package of a tablet containing trichloroisocyanuric acid according to (1) or (2), wherein the tablet further contains anhydrous sodium sulfate.
(4) The package of the tablet containing the trichloroisocyanuric acid according to any one of (1) to (3), wherein the tablet further contains an alkali metal carbonate and / or a hydrogen carbonate.
(5) The package of a tablet containing trichloroisocyanuric acid according to any one of (1) to (4), wherein the polyethylene terephthalate layer of the first layer has a thickness of 5 to 25 μm. ..
(6) Any of (1) to (5), wherein the thickness of the metal layer of the second layer is 1 to 20 μm, and the thickness of the polyethylene layer is 10 to 20 μm. A package of tablets containing the above-mentioned trichloroisocyanuric acid.
(7) The package of a tablet containing trichloroisocyanuric acid according to any one of (1) to (6), wherein the metal layer is an aluminum layer.
(8) The method according to any one of (1) to (7), wherein the resin forming the elastic resin layer of the third layer is either polypropylene, acrylic resin or ionomer resin. Package of tablets containing trichloroisocyanuric acid.
(9) The package of a tablet containing trichloroisocyanuric acid according to any one of (1) to (8), wherein the elastic resin layer of the third layer has a thickness of 20 to 50 μm. ..
本発明のＴＣＣＡ含有錠剤の包装体は、保存・保管期間において、ＴＣＣＡ含有錠剤の分解を大幅に低減することができる。
The package of the TCCA-containing tablet of the present invention can significantly reduce the decomposition of the TCCA-containing tablet during the storage and storage period.
以下、本発明のＴＣＣＡ含有錠剤の包装体について詳細に説明する。
Hereinafter, the package of the TCCA-containing tablet of the present invention will be described in detail.
１．ＴＣＣＡ含有錠剤
＜ＴＣＣＡ含有錠剤の成分＞
ＴＣＣＡ含有錠剤は主成分として、ＴＣＣＡを含有する。ＴＣＣＡは、［化１］の化学式で表される固体の化合物であって、水に投入した場合には、活性酸素と同様に強力な酸化能を有する活性塩素を放出して、水を次亜塩素酸水とすることができる。 1. 1. TCCA-containing tablets <Ingredients of TCCA-containing tablets>
TCCA-containing tablets contain TCCA as the main component. TCCA is a solid compound represented by the chemical formula of [Chemical formula 1], and when it is put into water, it releases active chlorine having a strong oxidizing ability similar to active oxygen, and makes water hypophilic. It can be chlorinated water.
＜ＴＣＣＡ含有錠剤の成分＞
ＴＣＣＡ含有錠剤は主成分として、ＴＣＣＡを含有する。ＴＣＣＡは、［化１］の化学式で表される固体の化合物であって、水に投入した場合には、活性酸素と同様に強力な酸化能を有する活性塩素を放出して、水を次亜塩素酸水とすることができる。 1. 1. TCCA-containing tablets <Ingredients of TCCA-containing tablets>
TCCA-containing tablets contain TCCA as the main component. TCCA is a solid compound represented by the chemical formula of [Chemical formula 1], and when it is put into water, it releases active chlorine having a strong oxidizing ability similar to active oxygen, and makes water hypophilic. It can be chlorinated water.
次亜塩素酸水は、ウイルスや菌類に対する高い殺菌作用を有しており、例えばノロウイルスやインフルエンザウイルスなどのウイルスや、黄色ブドウ球菌、炭疽菌、或いはサルモネラ菌などの菌類を不活性化することができる。
Hypochlorite water has a high bactericidal action against viruses and fungi, and can inactivate viruses such as norovirus and influenza virus, and fungi such as Staphylococcus aureus, anthrax, and salmonella. ..
次亜塩素酸は非常に不安定な物質であり、水溶液中で徐々に分解することが知られているが、ＴＣＣＡは水に対する溶解度が約１．２ｇであり、溶解速度が遅いので、水に投入した場合には、低濃度の活性ハロゲンを長時間に渡って放出することができる。
Hypochlorous acid is a very unstable substance and is known to gradually decompose in an aqueous solution, but TCCA has a solubility in water of about 1.2 g and a slow dissolution rate, so it can be dissolved in water. When charged, a low concentration of active halogen can be released over a long period of time.
ＴＣＣＡ含有錠剤を水に投入することにより、簡単かつ経済的に次亜塩素酸水を得ることができ、さらに、この次亜塩素酸水を噴霧することにより、各家庭、病院、保育所等の室内を簡単かつ経済的に除菌・消臭することができる。
Hypochlorite water can be obtained easily and economically by putting TCCA-containing tablets into water, and further, by spraying this hypochlorite water, each household, hospital, nursery school, etc. The room can be easily and economically sterilized and deodorized.
本発明の目的が達成される限り、ＴＣＣＡ含有錠剤には、ＴＣＣＡ以外に次のような添加剤を含有させることができる。
As long as the object of the present invention is achieved, the TCCA-containing tablet may contain the following additives in addition to TCCA.
増量剤（賦形剤）としては、芒硝、食塩の他、アルカリ金属の珪酸塩、炭酸塩、炭酸水素塩、燐酸塩、硫酸塩等が挙げられる。これらの内、芒硝は結晶水として水を含むことができ防湿剤として有用であることから特に好ましく、アルカリ金属の炭酸塩および／または炭酸水素塩はＴＣＣＡの加水分解に寄与し、次亜塩素酸の発生要因となることから特に好ましい。
Examples of bulking agents (injectors) include alkali metal silicates, carbonates, bicarbonates, phosphates, sulfates, etc., in addition to sardines and salt. Of these, sardine is particularly preferable because it can contain water as water of crystallization and is useful as a moisture barrier, and alkali metal carbonates and / or bicarbonates contribute to the hydrolysis of TCCA and hypochlorous acid. It is particularly preferable because it causes the occurrence of.
また、ＴＣＣＡ含有錠剤の成形性を高めるために、結合剤や滑沢剤を０．１～５重量％程度の割合で含有させることができる。成形性を高めることによって、ＴＣＣＡ含有錠剤の製造時や運送時に発生するＴＣＣＡ含有錠剤の欠けや割れを防止することができる。結合剤としては、固形粒子を結合する機能を有し、好ましくは水溶性のものであれば特に限定されないが、例えばカルボキシメチルセルロース、カルボキシメチルセルロースナトリウム、デキストリン、ポリエチレングリコール、ポリビニルアルコール、ポリアルキレングリコール、リグニンスルホン酸塩、アラビアゴム、デンプン類、ショ糖などが挙げられる。滑沢剤としては、固形粒子の流動性、充填性、付着性を改善する機能を有するものであれば特に限定されないが、例えばステアリン酸カルシウム、ステアリン酸マグネシウム、ステアリン酸ナトリウム、安息香酸ナトリウム、オルトほう酸、タルク等が挙げられる。
Further, in order to improve the moldability of the TCCA-containing tablet, a binder or a lubricant can be contained in a proportion of about 0.1 to 5% by weight. By improving the moldability, it is possible to prevent the TCCA-containing tablet from being chipped or cracked, which occurs during the production or transportation of the TCCA-containing tablet. The binder has a function of binding solid particles and is preferably water-soluble, but is not particularly limited. For example, carboxymethyl cellulose, sodium carboxymethyl cellulose, dextrin, polyethylene glycol, polyvinyl alcohol, polyalkylene glycol, lignin. Examples include sulfonate, gum arabic, starches, sucrose and the like. The lubricant is not particularly limited as long as it has a function of improving the fluidity, filling property and adhesiveness of solid particles, and for example, calcium stearate, magnesium stearate, sodium stearate, sodium benzoate, orthoboric acid. , Talc, etc.
また、ＴＣＣＡ含有錠剤の溶解性を高めるために、過硫酸塩、過炭酸塩又は過ホウ酸塩を発泡剤や崩壊剤を含有させることができる。発泡剤は、酸性物質およびアルカリ性物質の組合せからなり、ＴＣＣＡ含有錠剤を水に投入すると両者が反応してガスを発生するので、ＴＣＣＡ含有錠剤の崩壊性を高めることができる。酸性物質としては、例えばクエン酸、酒石酸、シュウ酸、コハク酸、マレイン酸、フタル酸、リンゴ酸、アジピン酸等の有機酸、リン酸二水素ナトリウム、リン酸二水素カリウム、リン酸二水素アンモニウム、硫酸水素カリウム等の水素塩、カリミョウバン、アンモニウムミョウバン等のミョウバン類などが挙げられる。アルカリ性物質としては、例えば炭酸ナトリウム、炭酸カリウム、炭酸カルシウム、炭酸マグネシウム、炭酸アンモニウム等の炭酸塩、重炭酸ナトリウム、重炭酸カリウム等の重炭酸塩等が挙げられる。崩壊剤は、ＴＣＣＡ含有錠剤を水に投入すると吸水して膨潤、あるいは、炭酸ガスを発生して発泡してＴＣＣＡ含有錠剤を崩壊させることができ、例えばカルボキシメチルセルロースカルシウム、架橋ポリビニルピロリドン、低置換度ヒドロキシプロピルセルロース等が挙げられる。なお前述したデンプンは、結合剤としても機能するが、崩壊剤としての機能も有している。
Further, in order to increase the solubility of TCCA-containing tablets, persulfate, percarbonate or perborate can be contained as a foaming agent or a disintegrant. The foaming agent is composed of a combination of an acidic substance and an alkaline substance, and when the TCCA-containing tablet is put into water, both react to generate gas, so that the disintegration property of the TCCA-containing tablet can be enhanced. Examples of acidic substances include organic acids such as citric acid, tartaric acid, oxalic acid, succinic acid, maleic acid, phthalic acid, malic acid and adipic acid, sodium dihydrogen phosphate, potassium dihydrogen phosphate and ammonium dihydrogen phosphate. , Hydrogen salts such as potassium hydrogen sulfate, and myobans such as carimyoban and ammonium myoban. Examples of the alkaline substance include carbonates such as sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate and ammonium carbonate, and bicarbonates such as sodium bicarbonate and potassium bicarbonate. The disintegrant can absorb water and swell when the TCCA-containing tablet is put into water, or generate carbon dioxide gas and foam to disintegrate the TCCA-containing tablet. For example, carboxymethyl cellulose calcium, crosslinked polyvinylpyrrolidone, and low degree of substitution. Hydroxypropyl cellulose and the like can be mentioned. The starch described above also functions as a binder, but also has a function as a disintegrant.
また、ＴＣＣＡ含有錠剤を着色あるいは賦香するために、従来知られた染料、顔料あるいは香料をＴＣＣＡ含有錠剤に含有させることができる。この場合、過硫酸塩、過炭酸塩又は過ホウ酸塩や、ＴＣＣＡ又はハロゲン化ヒダントイン化合物と接触させることを避けるために、増量剤（賦形剤）と共に染料、顔料あるいは香料を含有する層を別に設ける構成としてもよい。
Further, in order to color or perfume the TCCA-containing tablet, conventionally known dyes, pigments or fragrances can be contained in the TCCA-containing tablet. In this case, in order to avoid contact with persulfates, percarbonates or perborates, TCCA or halogenated hydantin compounds, a layer containing a dye, pigment or fragrance together with a bulking agent (excipient) is provided. It may be provided separately.
＜ＴＣＣＡ含有錠剤の成形＞
ＴＣＣＡ含有錠剤は、粉末または顆粒のＴＣＣＡ等の原料を金型の中に充填し加圧する方法（以下、「打錠」ともいう。）よって製造される。工業的に製造する際には、金型（臼杵）および加圧装置から構成される公知の加圧式打錠機が好ましく使用される。 <Formation of TCCA-containing tablets>
TCCA-containing tablets are produced by a method of filling a mold with a raw material such as powder or granules of TCCA and pressurizing the mold (hereinafter, also referred to as "tablet"). In industrial production, a known pressure-type locking machine composed of a mold (usuki) and a pressurizing device is preferably used.
ＴＣＣＡ含有錠剤は、粉末または顆粒のＴＣＣＡ等の原料を金型の中に充填し加圧する方法（以下、「打錠」ともいう。）よって製造される。工業的に製造する際には、金型（臼杵）および加圧装置から構成される公知の加圧式打錠機が好ましく使用される。 <Formation of TCCA-containing tablets>
TCCA-containing tablets are produced by a method of filling a mold with a raw material such as powder or granules of TCCA and pressurizing the mold (hereinafter, also referred to as "tablet"). In industrial production, a known pressure-type locking machine composed of a mold (usuki) and a pressurizing device is preferably used.
すなわち、原料を臼へ順次投入し、加圧装置を介して臼と杵との間に圧力を加えると、原料が圧着されて、臼と杵とで形成される形状を有するＴＣＣＡ含有錠剤が製造される。
That is, when the raw materials are sequentially charged into the mortar and pressure is applied between the mortar and the pestle via a pressurizing device, the raw materials are crimped to produce a TCCA-containing tablet having a shape formed by the mortar and the pestle. Will be done.
このような加圧式打錠機としては、一錠ずつ打錠する単発式打錠機や複数の金型（臼杵）を、回転する円盤に沿って装着し、これが１回転する間に、原料の充填、加圧成形、ＴＣＣＡ含有錠剤の取り出しと云う一連の作業を連続的に行えるロータリー式打錠機を用いることができる。単発式打錠機としては、例えば、ＲＩＶＡ社製「ＭＩＮＩＰＲＥＳＳＭ II」、同「ＰＩＣＣＯＬＡ」、菊水製作所社製堅型粉末成型機、岡田精工社製単発打錠機、富士薬品機械社製スタンディングプレス等が挙げられる。また、ロータリー式打錠機としては、例えば、モリマシナリー社製「ロータリープレスＴＲＰシリーズ」、菊水製作所社製「クリーンプレスシリーズ」、同「タフプレスシリーズ」、ＦＥＴＴＥ社製「Ｐシリーズ」、同「ＰＴシリーズ」、ＫＯＲＳＣＨ社製「ＰＨシリーズ」、畑鐵工所社製「Ｂシリーズ」等が挙げられる。
As such a pressure-type tableting machine, a single-shot tableting machine that locks one tablet at a time and a plurality of dies (molds) are mounted along a rotating disk, and the raw material is used during one rotation. A rotary tableting machine capable of continuously performing a series of operations such as filling, pressure molding, and taking out TCCA-containing tablets can be used. Examples of single-shot lockers include RIVA's "MINIPRESSM II" and "PICCOLA", Kikusui Seisakusho's rigid powder molding machine, Okada Seiko's single-shot locker, and Fuji Yakuhin Kikai's standing press. Can be mentioned. Examples of rotary lockers include "Rotary Press TRP Series" manufactured by Mori Machinery Co., Ltd., "Clean Press Series" manufactured by Kikusui Seisakusho Co., Ltd., "Tough Press Series", "P Series" manufactured by FETTE Co., Ltd., and "P Series". Examples include "PT series", "PH series" manufactured by KORSCH, and "B series" manufactured by Hata Iron Works.
＜ＴＣＣＡ含有錠剤の重量＞
次亜塩素酸水は、強酸性次亜塩素酸水（ｐＨ２．７以下、有効塩素濃度２０～６０ｐｐｍ）、弱酸性次亜塩素酸水（ｐＨ２．７～５．０、有効塩素濃度１０～６０ｐｐｍ）、微酸性次亜塩素酸水（ｐＨ５．０～６．５、有効塩素濃度１０～８０ｐｐｍ）の３種に区分できるが、微酸性次亜塩素酸水は、ｐＨ値が人間の肌と同程度であるため、高い殺菌作用を有しながらも、安全性に優れるといった特徴がある。また、塩素系殺菌剤特有の塩素臭が残留することがないといった特徴を有している。 <Weight of TCCA-containing tablets>
Hypochlorous acid water is strongly acidic hypochlorous acid water (pH 2.7 or less, effective chlorine concentration 20 to 60 ppm), weakly acidic hypochlorous acid water (pH 2.7 to 5.0, effective chlorine concentration 10 to 60 ppm). ), Slightly acidic hypochlorous acid water (pH 5.0 to 6.5, effective chlorine concentration 10 to 80 ppm), but the slightly acidic hypochlorous acid water has the same pH value as human skin. Because of the degree, it has a feature of being excellent in safety while having a high bactericidal action. In addition, it has the feature that the chlorine odor peculiar to chlorine-based bactericides does not remain.
次亜塩素酸水は、強酸性次亜塩素酸水（ｐＨ２．７以下、有効塩素濃度２０～６０ｐｐｍ）、弱酸性次亜塩素酸水（ｐＨ２．７～５．０、有効塩素濃度１０～６０ｐｐｍ）、微酸性次亜塩素酸水（ｐＨ５．０～６．５、有効塩素濃度１０～８０ｐｐｍ）の３種に区分できるが、微酸性次亜塩素酸水は、ｐＨ値が人間の肌と同程度であるため、高い殺菌作用を有しながらも、安全性に優れるといった特徴がある。また、塩素系殺菌剤特有の塩素臭が残留することがないといった特徴を有している。 <Weight of TCCA-containing tablets>
Hypochlorous acid water is strongly acidic hypochlorous acid water (pH 2.7 or less, effective chlorine concentration 20 to 60 ppm), weakly acidic hypochlorous acid water (pH 2.7 to 5.0, effective chlorine concentration 10 to 60 ppm). ), Slightly acidic hypochlorous acid water (pH 5.0 to 6.5, effective chlorine concentration 10 to 80 ppm), but the slightly acidic hypochlorous acid water has the same pH value as human skin. Because of the degree, it has a feature of being excellent in safety while having a high bactericidal action. In addition, it has the feature that the chlorine odor peculiar to chlorine-based bactericides does not remain.
ＴＣＣＡ含有錠剤の重量に特に限定はないが、次亜塩素酸水を噴霧するスプレー、噴霧装置、加湿装置等の装置の貯水槽を満たした水を、微酸性次亜塩素酸水にできる範囲とすることが利用しやすさの面から好ましい。ＴＣＣＡ含有錠剤をこのような重量とすると、貯水槽に水を満たし、ここにＴＣＣＡ含有錠剤を１錠投入するという簡単な操作により、微酸性次亜塩素酸水を得ることができる。
The weight of the TCCA-containing tablet is not particularly limited, but the range in which the water that fills the water tank of the device such as a spray, a spray device, a humidifier, etc. that sprays hypochlorite water can be made into slightly acidic hypochlorite water. It is preferable from the viewpoint of ease of use. When the TCCA-containing tablet has such a weight, a slightly acidic hypochloroisocyanuric acid water can be obtained by a simple operation of filling a water tank with water and putting one TCCA-containing tablet into the water tank.
一般に、０．５ｇのＴＣＣＡを主成分とするＴＣＣＡ含有錠剤を、５００ｍｌの水道水に投入した場合には、ｐＨ５．５．～６．９（水道水のアルカリ度により異なる）の微酸性次亜塩素酸水が得られることから、ＴＣＣＡ含有錠剤の重量は０．３～１．０ｇとするのが好ましい。
Generally, when 0.5 g of TCCA-containing tablets containing 0.5 g of TCCA as a main component is put into 500 ml of tap water, the pH is 5.5. Since slightly acidic hypochlorite water of up to 6.9 (depending on the alkalinity of tap water) can be obtained, the weight of the TCCA-containing tablet is preferably 0.3 to 1.0 g.
＜ＴＣＣＡ含有錠剤の形状＞
ＴＣＣＡ含有錠剤の形状に特に限定はなく、打錠しやすさ、取り扱い・使用しやすさ等の観点から適宜形状を決定することができる。ＴＣＣＡ含有錠剤の形状としては、例えば円柱形や、立方体、直方体形等が挙げられるが、上記の観点から、円柱形とするのが好ましい。 <Shape of TCCA-containing tablets>
The shape of the TCCA-containing tablet is not particularly limited, and the shape can be appropriately determined from the viewpoint of ease of tableting, ease of handling, and ease of use. Examples of the shape of the TCCA-containing tablet include a cylindrical shape, a cubic shape, a rectangular parallelepiped shape, and the like, but from the above viewpoint, the cylindrical shape is preferable.
ＴＣＣＡ含有錠剤の形状に特に限定はなく、打錠しやすさ、取り扱い・使用しやすさ等の観点から適宜形状を決定することができる。ＴＣＣＡ含有錠剤の形状としては、例えば円柱形や、立方体、直方体形等が挙げられるが、上記の観点から、円柱形とするのが好ましい。 <Shape of TCCA-containing tablets>
The shape of the TCCA-containing tablet is not particularly limited, and the shape can be appropriately determined from the viewpoint of ease of tableting, ease of handling, and ease of use. Examples of the shape of the TCCA-containing tablet include a cylindrical shape, a cubic shape, a rectangular parallelepiped shape, and the like, but from the above viewpoint, the cylindrical shape is preferable.
ＴＣＣＡ含有錠剤の形状を円柱形とした場合には、その径を５～１５ｍｍ、その高さを２～６ｍｍとすることが実用上好ましい。
When the shape of the TCCA-containing tablet is cylindrical, it is practically preferable that the diameter is 5 to 15 mm and the height is 2 to 6 mm.
２．ＴＣＣＡ含有錠剤の包装体
まず、［図１］～［図３］を用いて、本件発明のＴＣＣＡ含有錠剤の包装体の概要について説明する。 2. 2. Packaging of TCCA-Containing Tablets First, the outline of the packaging of TCCA-containing tablets of the present invention will be described with reference to FIGS. 1 to 3.
まず、［図１］～［図３］を用いて、本件発明のＴＣＣＡ含有錠剤の包装体の概要について説明する。 2. 2. Packaging of TCCA-Containing Tablets First, the outline of the packaging of TCCA-containing tablets of the present invention will be described with reference to FIGS. 1 to 3.
本件発明のＴＣＣＡ含有錠剤の包装体では、［図１］に示すように、
ａ）ポリエチレンテレフタレート層（１－１）からなる第１層（１）、
ｂ）上記第１層（１）上に積層された、上記第１層（１）側から金属層（２－２）およびポリエチレン層（２－１）からなる第２層（２）、および
ｃ）上記第２層（２）上に積層された、弾性樹脂層（３－１）からなる第３層（３）
を有する積層フィルム（４）が用いられる。 In the package of the TCCA-containing tablet of the present invention, as shown in [Fig. 1],
a) A first layer (1) composed of a polyethylene terephthalate layer (1-1),
b) A second layer (2) laminated on the first layer (1) and composed of a metal layer (2-2) and a polyethylene layer (2-1) from the first layer (1) side, and c. ) A third layer (3) composed of an elastic resin layer (3-1) laminated on the second layer (2).
The laminated film (4) having the above is used.
ａ）ポリエチレンテレフタレート層（１－１）からなる第１層（１）、
ｂ）上記第１層（１）上に積層された、上記第１層（１）側から金属層（２－２）およびポリエチレン層（２－１）からなる第２層（２）、および
ｃ）上記第２層（２）上に積層された、弾性樹脂層（３－１）からなる第３層（３）
を有する積層フィルム（４）が用いられる。 In the package of the TCCA-containing tablet of the present invention, as shown in [Fig. 1],
a) A first layer (1) composed of a polyethylene terephthalate layer (1-1),
b) A second layer (2) laminated on the first layer (1) and composed of a metal layer (2-2) and a polyethylene layer (2-1) from the first layer (1) side, and c. ) A third layer (3) composed of an elastic resin layer (3-1) laminated on the second layer (2).
The laminated film (4) having the above is used.
そして、［図２］および［図３］に示すように、ＴＣＣＡ含有錠剤（５）は、２枚の積層フィルム（４）により、第１層（１）が対面するように上下方向から挟持される。ＴＣＣＡ含有錠剤（５）を上下方向から挟持する２枚の積層フィルム（４）としては、２枚の別々の積層フィルムを用いても良いし、１枚の積層フィルムを折り返して用いても良い。
Then, as shown in [FIG. 2] and [FIG. 3], the TCCA-containing tablet (5) is sandwiched by the two laminated films (4) from above and below so that the first layer (1) faces each other. To. As the two laminated films (4) that sandwich the TCCA-containing tablet (5) from above and below, two separate laminated films may be used, or one laminated film may be folded back and used.
そして、ＴＣＣＡ含有錠剤（５）を挟持した上下の積層フィルムは、溶着部分Ａにおいて溶着され、ＴＣＣＡ含有錠剤（５）が密封されることとなる。
Then, the upper and lower laminated films sandwiching the TCCA-containing tablet (5) are welded at the welded portion A, and the TCCA-containing tablet (5) is sealed.
＜積層フィルム（４）＞
通常の錠剤の包装体においても、ガスバリア性を改善するために、金属フィルムが用いられる。具体的には、錠剤側から、耐薬品性、熱溶着性等に優れるポリエチレンテレフタレート層からなるＡ－ａ層、および、該ポリエチレンテレフタレート層に設けられた金属層であるＡ－ｂ層からなるＡ層、ならびに該金属層Ａ－ｂを保護する弾性樹脂層からなるＢ層を有する積層フィルムが用いられる。 <Laminated film (4)>
A metal film is also used in the packaging of ordinary tablets in order to improve the gas barrier property. Specifically, from the tablet side, A is composed of an Aa layer made of a polyethylene terephthalate layer having excellent chemical resistance, heat welding resistance, etc., and an Ab layer made of a metal layer provided on the polyethylene terephthalate layer. A laminated film having a layer and a layer B composed of an elastic resin layer that protects the metal layer Ab is used.
通常の錠剤の包装体においても、ガスバリア性を改善するために、金属フィルムが用いられる。具体的には、錠剤側から、耐薬品性、熱溶着性等に優れるポリエチレンテレフタレート層からなるＡ－ａ層、および、該ポリエチレンテレフタレート層に設けられた金属層であるＡ－ｂ層からなるＡ層、ならびに該金属層Ａ－ｂを保護する弾性樹脂層からなるＢ層を有する積層フィルムが用いられる。 <Laminated film (4)>
A metal film is also used in the packaging of ordinary tablets in order to improve the gas barrier property. Specifically, from the tablet side, A is composed of an Aa layer made of a polyethylene terephthalate layer having excellent chemical resistance, heat welding resistance, etc., and an Ab layer made of a metal layer provided on the polyethylene terephthalate layer. A laminated film having a layer and a layer B composed of an elastic resin layer that protects the metal layer Ab is used.
一方、本件発明のＴＣＣＡ含有錠剤の包装体では、ＴＣＣＡ含有錠剤はわずかな水分で加水分解して次亜塩素酸を生じ、これが塩化水素と遊離の酸素に分解し、金属層を腐食するため、保存・保管期間においてＴＣＣＡの分解が促進されてしまう。
On the other hand, in the package of the TCCA-containing tablet of the present invention, the TCCA-containing tablet is hydrolyzed with a small amount of water to generate hypochlorous acid, which is decomposed into hydrogen chloride and free oxygen and corrodes the metal layer. Decomposition of TCCA is promoted during the storage / storage period.
本件発明の積層フィルム（４）では、上記Ａ－ａ層に相当する第１層（１）、上記Ａ－ｂ層に相当する第２層（２）の金属層（２－２）、および上記Ｂ層に相当する第３層（３）に加え、第２層（２）のポリエチレン層（２－１）を設けることにより、包装体外部からの水分の透過、およびＴＣＣＡ含有錠剤からの塩化水素の透過を大幅に抑制し、保存・保管期間におけるＴＣＣＡ含有錠剤の分解を大幅に低減することができる。
In the laminated film (4) of the present invention, the first layer (1) corresponding to the Aa layer, the metal layer (2-2) of the second layer (2) corresponding to the AB layer, and the above. By providing the polyethylene layer (2-1) of the second layer (2) in addition to the third layer (3) corresponding to the B layer, moisture permeates from the outside of the package and hydrogen chloride from the TCCA-containing tablet. Permeation can be significantly suppressed, and decomposition of TCCA-containing tablets during the storage and storage period can be significantly reduced.
また、後に述べる実施例１、比較例１に示すように、驚くべきことに、第２層（２）として、金属層（２－２）を有するポリエチレン層（２－１）を用いることにより、保存・保管期間におけるＴＣＣＡ含有錠剤の分解を大幅に低減することができる。
Further, as shown in Example 1 and Comparative Example 1 described later, surprisingly, by using a polyethylene layer (2-1) having a metal layer (2-2) as the second layer (2), Decomposition of TCCA-containing tablets during the storage / storage period can be significantly reduced.
＜包装体の態様＞
本件発明のＴＣＣＡ含有錠剤の包装体は、ＴＣＣＡ含有錠剤を２枚の積層フィルムによって第１層が対面するように上下方向から挟持し、この２枚の積層フィルムの溶着により密封してなるものであるが、［図２］に示す第１実施形態のように、予め賦形していない積層フィルム（４）を用いても良いし、［図３］に示す第２実施形態のように、ＴＣＣＡ含有錠剤（５）の収容部に対応する部分を予め凹状に賦形した積層フィルム（４）を用いても良い。 <Aspect of packaging>
The package of the TCCA-containing tablet of the present invention is formed by sandwiching the TCCA-containing tablet from above and below with two laminated films so that the first layer faces each other, and sealing by welding the two laminated films. However, a laminated film (4) that has not been shaped in advance may be used as in the first embodiment shown in [FIG. 2], or TCCA as in the second embodiment shown in [FIG. 3]. A laminated film (4) in which a portion corresponding to the accommodating portion of the contained tablet (5) is formed in a concave shape in advance may be used.
本件発明のＴＣＣＡ含有錠剤の包装体は、ＴＣＣＡ含有錠剤を２枚の積層フィルムによって第１層が対面するように上下方向から挟持し、この２枚の積層フィルムの溶着により密封してなるものであるが、［図２］に示す第１実施形態のように、予め賦形していない積層フィルム（４）を用いても良いし、［図３］に示す第２実施形態のように、ＴＣＣＡ含有錠剤（５）の収容部に対応する部分を予め凹状に賦形した積層フィルム（４）を用いても良い。 <Aspect of packaging>
The package of the TCCA-containing tablet of the present invention is formed by sandwiching the TCCA-containing tablet from above and below with two laminated films so that the first layer faces each other, and sealing by welding the two laminated films. However, a laminated film (4) that has not been shaped in advance may be used as in the first embodiment shown in [FIG. 2], or TCCA as in the second embodiment shown in [FIG. 3]. A laminated film (4) in which a portion corresponding to the accommodating portion of the contained tablet (5) is formed in a concave shape in advance may be used.
本件発明のＴＣＣＡ含有錠剤の包装体としては、複数個のＴＣＣＡ含有錠剤が積層フィルムの溶着によりそれぞれ個別に密封されたものが好ましい。複数個のＴＣＣＡ含有錠剤をそれぞれ個別に密封することにより、包装体の一部の密封が破れた場合でも、分解により悪影響を受けるＴＣＣＡ含有錠剤の数を少なくできる。
As the package of the TCCA-containing tablet of the present invention, it is preferable that a plurality of TCCA-containing tablets are individually sealed by welding of a laminated film. By individually sealing each of the plurality of TCCA-containing tablets, the number of TCCA-containing tablets that are adversely affected by decomposition can be reduced even if a part of the package is broken.
＜ＴＣＣＡ含有錠剤の添加成分＞
本件発明のＴＣＣＡ含有錠剤の包装体で用いるＴＣＣＡ含有錠剤には、無水硫酸ナトリウムを含有させることが好ましい。ＴＣＣＡ含有錠剤に無水硫酸ナトリウムを含有させることにより、ＴＣＣＡ含有錠剤の密封部分に水蒸気等の水分が多少侵入しても、無水硫酸ナトリウムにより水分を結晶水として固定でき、ＴＣＣＡ含有錠剤の分解を回避できる。 <Additional components of TCCA-containing tablets>
It is preferable that the TCCA-containing tablet used in the packaging of the TCCA-containing tablet of the present invention contains anhydrous sodium sulfate. By containing anhydrous sodium sulfate in the TCCA-containing tablet, even if some water such as water vapor invades the sealed portion of the TCCA-containing tablet, the water can be fixed as water of crystallization by the anhydrous sodium sulfate, and decomposition of the TCCA-containing tablet is avoided. it can.
本件発明のＴＣＣＡ含有錠剤の包装体で用いるＴＣＣＡ含有錠剤には、無水硫酸ナトリウムを含有させることが好ましい。ＴＣＣＡ含有錠剤に無水硫酸ナトリウムを含有させることにより、ＴＣＣＡ含有錠剤の密封部分に水蒸気等の水分が多少侵入しても、無水硫酸ナトリウムにより水分を結晶水として固定でき、ＴＣＣＡ含有錠剤の分解を回避できる。 <Additional components of TCCA-containing tablets>
It is preferable that the TCCA-containing tablet used in the packaging of the TCCA-containing tablet of the present invention contains anhydrous sodium sulfate. By containing anhydrous sodium sulfate in the TCCA-containing tablet, even if some water such as water vapor invades the sealed portion of the TCCA-containing tablet, the water can be fixed as water of crystallization by the anhydrous sodium sulfate, and decomposition of the TCCA-containing tablet is avoided. it can.
＜積層フィルム（４）の第１層（１）＞
積層フィルム（４）の第１層（１）［すなわち、包装されるＴＣＣＡ含有錠剤（５）と接する層］は、本件発明の包装体の基本素材となるものであり、機械的、物理的、化学的において優れた性質を有するポリエチレンテレフタレート層（１－１）を用いて形成される。 <First layer (1) of laminated film (4)>
The first layer (1) of the laminated film (4) [that is, the layer in contact with the TCCA-containing tablet (5) to be packaged] is a basic material of the package of the present invention, and is mechanically and physically. It is formed using a polyethylene terephthalate layer (1-1) having excellent chemical properties.
積層フィルム（４）の第１層（１）［すなわち、包装されるＴＣＣＡ含有錠剤（５）と接する層］は、本件発明の包装体の基本素材となるものであり、機械的、物理的、化学的において優れた性質を有するポリエチレンテレフタレート層（１－１）を用いて形成される。 <First layer (1) of laminated film (4)>
The first layer (1) of the laminated film (4) [that is, the layer in contact with the TCCA-containing tablet (5) to be packaged] is a basic material of the package of the present invention, and is mechanically and physically. It is formed using a polyethylene terephthalate layer (1-1) having excellent chemical properties.
ポリエチレンテレフタレート層（１－１）としては、未延伸フィルムあるいは１軸方向または２軸方向に延伸した延伸フィルム等のいずれも使用できるが、機械的強度の観点からは、２軸方向に延伸した延伸フィルムを用いるのが好ましい。
As the polyethylene terephthalate layer (1-1), either an unstretched film or a stretched film stretched in the uniaxial direction or the biaxial direction can be used, but from the viewpoint of mechanical strength, the stretched film stretched in the biaxial direction can be used. It is preferable to use a film.
ポリエチレンテレフタレート層（１－１）の厚さは、５～２５μｍが好ましく、１０～２０μｍがより好ましい。ポリエチレンテレフタレート層（１－１）の厚さが５μｍ以上であると包装体外部からの水分の透過、およびＴＣＣＡ含有錠剤からの塩化水素の透過を低減することができ、２５μｍ以下であると積層フィルムの溶着を好適に行うことができる。
The thickness of the polyethylene terephthalate layer (1-1) is preferably 5 to 25 μm, more preferably 10 to 20 μm. When the thickness of the polyethylene terephthalate layer (1-1) is 5 μm or more, the permeation of water from the outside of the package and the permeation of hydrogen chloride from the TCCA-containing tablet can be reduced, and when it is 25 μm or less, the laminated film. Can be preferably welded.
＜積層フィルム（４）の第２層（２）＞
積層フィルム（４）の第２層（２）［すなわち、積層フィルム（４）の中間層］は、包装体外部からの水分の透過、およびＴＣＣＡ含有錠剤（５）からの塩化水素の透過を低減するために、第１層（１）側から、金属層（２－２）およびポリエチレン層（２－１）を配している。 <Second layer (2) of laminated film (4)>
The second layer (2) of the laminated film (4) [that is, the intermediate layer of the laminated film (4)] reduces the permeation of water from the outside of the package and the permeation of hydrogen chloride from the TCCA-containing tablet (5). In order to do so, a metal layer (2-2) and a polyethylene layer (2-1) are arranged from the first layer (1) side.
積層フィルム（４）の第２層（２）［すなわち、積層フィルム（４）の中間層］は、包装体外部からの水分の透過、およびＴＣＣＡ含有錠剤（５）からの塩化水素の透過を低減するために、第１層（１）側から、金属層（２－２）およびポリエチレン層（２－１）を配している。 <Second layer (2) of laminated film (4)>
The second layer (2) of the laminated film (4) [that is, the intermediate layer of the laminated film (4)] reduces the permeation of water from the outside of the package and the permeation of hydrogen chloride from the TCCA-containing tablet (5). In order to do so, a metal layer (2-2) and a polyethylene layer (2-1) are arranged from the first layer (1) side.
本件発明の積層フィルム（４）では、積層フィルム（４）の中間層として、第１層（１）側から、金属層（２－２）およびポリエチレン層（２－１）を配することにより、包装体外部からの水分の透過、およびＴＣＣＡ含有錠剤からの塩化水素の透過を大幅に抑制し、保存・保管期間におけるＴＣＣＡ含有錠剤の分解を大幅に低減することができる。
In the laminated film (4) of the present invention, a metal layer (2-2) and a polyethylene layer (2-1) are arranged from the first layer (1) side as an intermediate layer of the laminated film (4). It is possible to significantly suppress the permeation of water from the outside of the package and the permeation of hydrogen chloride from the TCCA-containing tablet, and significantly reduce the decomposition of the TCCA-containing tablet during the storage / storage period.
ポリエチレン層（２－１）に金属層（２－２）を設ける方法としては、押出ラミネート、蒸着等の公知の方法を適宜用いることができる。
As a method of providing the metal layer (2-2) on the polyethylene layer (2-1), a known method such as extrusion lamination or vapor deposition can be appropriately used.
金属層（２－２）に用いられる金属としては、アルミニウム、酸化珪素、酸化アルミニウム、酸化インジウム、酸化錫、酸化ジルコニウム等が挙げられるが、ガスバリア性、耐食性、汎用性等の観点からアルミニウムが好ましい。金属層（２－２）の厚さは、１～２０μｍが好ましく、５～１０μｍがより好ましい。金属層（２－２）の厚さが５μｍ以上であると包装体外部からの水分の透過、およびＴＣＣＡ含有錠剤からの塩化水素の透過を十分に低減でき、２０μｍ以下であると強度が高くなりすぎず十分な成形性を得ることができる。
Examples of the metal used for the metal layer (2-2) include aluminum, silicon oxide, aluminum oxide, indium oxide, tin oxide, and zirconium oxide, but aluminum is preferable from the viewpoint of gas barrier property, corrosion resistance, versatility, and the like. .. The thickness of the metal layer (2-2) is preferably 1 to 20 μm, more preferably 5 to 10 μm. When the thickness of the metal layer (2-2) is 5 μm or more, the permeation of water from the outside of the package and the permeation of hydrogen chloride from the TCCA-containing tablet can be sufficiently reduced, and when the thickness is 20 μm or less, the strength becomes high. Sufficient moldability can be obtained without too much.
ポリエチレン層（２－１）としては、未延伸フィルムあるいは１軸方向または２軸方向に延伸した延伸フィルム等のいずれも使用できるが、機械的強度の観点からは、２軸方向に延伸した延伸フィルムを用いるのが好ましい。
As the polyethylene layer (2-1), either an unstretched film or a stretched film stretched in a uniaxial direction or a biaxial direction can be used, but from the viewpoint of mechanical strength, a stretched film stretched in the biaxial direction. Is preferably used.
ポリエチレン層（２－１）の厚さは、５～２５μｍが好ましく、１０～２０μｍがより好ましい。ポリエチレン層（２－１）の厚さを５～２５μｍとすることにより、金属層（２－２）を均一に設けることができる。
The thickness of the polyethylene layer (2-1) is preferably 5 to 25 μm, more preferably 10 to 20 μm. By setting the thickness of the polyethylene layer (2-1) to 5 to 25 μm, the metal layer (2-2) can be uniformly provided.
＜積層フィルム（４）の第３層（３）＞
積層フィルム（４）の第３層（３）［すなわち、積層フィルム（４）の最外層］は、第２層（２）を保護するために、弾性樹脂層（３－１）を用いて形成される。 <Third layer (3) of laminated film (4)>
The third layer (3) of the laminated film (4) [that is, the outermost layer of the laminated film (4)] is formed by using an elastic resin layer (3-1) to protect the second layer (2). Will be done.
積層フィルム（４）の第３層（３）［すなわち、積層フィルム（４）の最外層］は、第２層（２）を保護するために、弾性樹脂層（３－１）を用いて形成される。 <Third layer (3) of laminated film (4)>
The third layer (3) of the laminated film (4) [that is, the outermost layer of the laminated film (4)] is formed by using an elastic resin layer (3-1) to protect the second layer (2). Will be done.
弾性樹脂層（３－１）に用いられる樹脂としては、ポリプロピレン、アクリル系樹脂、アイオノマー樹脂等の弾性を有する樹脂を用いることができるが、硬質かつ弾性に優れたポリプロピレンが好ましい。
As the resin used for the elastic resin layer (3-1), a resin having elasticity such as polypropylene, acrylic resin, ionomer resin and the like can be used, but polypropylene having excellent hardness and elasticity is preferable.
弾性樹脂層（３－１）の厚さは、金属層（２－２）を適正に固定・保護できるものであれば良く、使用する樹脂によっても異なるが、一般的には２０～５０μｍが好ましい。
The thickness of the elastic resin layer (3-1) may be any as long as it can properly fix and protect the metal layer (2-2), and varies depending on the resin used, but is generally preferably 20 to 50 μm. ..
以下に実施例１～２および比較例１～２に基づいて本件発明のＴＣＣＡ含有錠剤の包装体をより具体的に説明するが、本件発明は以下の実施例に何ら限定されるものではない。
The packaging of the TCCA-containing tablet of the present invention will be described in more detail below based on Examples 1 and 2 and Comparative Examples 1 and 2, but the present invention is not limited to the following examples.
＜ＴＣＣＡ含有錠剤の作成＞
下記［表１］に示す処方に従って、即ち、処方成分をヘンシェルミキサーで混合した後、１ｇを秤量し、打錠機で打錠して錠剤を得た。この錠剤を水道水５Ｌで溶かしたところ、直ちに溶解し、ｐＨは６．５で次亜塩素酸の濃度は２００ｐｐｍであった。 <Preparation of TCCA-containing tablets>
According to the formulation shown in [Table 1] below, that is, after mixing the formulation components with a Henschel mixer, 1 g was weighed and tableted with a tableting machine to obtain tablets. When this tablet was dissolved in 5 L of tap water, it was immediately dissolved, and the pH was 6.5 and the concentration of hypochlorous acid was 200 ppm.
下記［表１］に示す処方に従って、即ち、処方成分をヘンシェルミキサーで混合した後、１ｇを秤量し、打錠機で打錠して錠剤を得た。この錠剤を水道水５Ｌで溶かしたところ、直ちに溶解し、ｐＨは６．５で次亜塩素酸の濃度は２００ｐｐｍであった。 <Preparation of TCCA-containing tablets>
According to the formulation shown in [Table 1] below, that is, after mixing the formulation components with a Henschel mixer, 1 g was weighed and tableted with a tableting machine to obtain tablets. When this tablet was dissolved in 5 L of tap water, it was immediately dissolved, and the pH was 6.5 and the concentration of hypochlorous acid was 200 ppm.
上記ＴＣＣＡ含有錠剤を用いて、以下の実施例１～２・比較例１～２のようにＴＣＣＡ含有錠剤の包装体を作成し、下記の＜安定性試験＞を行った。
Using the above TCCA-containing tablets, a package of TCCA-containing tablets was prepared as in Examples 1 and 2 and Comparative Examples 1 and 2 below, and the following <stability test> was performed.
なお、以下の実施例１～２・比較例１～２では、次のａ）～ｄ）の素材を用いた。
ａ）ポリエチレンテレフタレート：東洋紡績株式会社製、商品名「ＰＥＴ１２」
ｂ）アルミニウム：株式会社ＵＡＣＪ製、商品名「ＡＬ７」
ｃ）ポリエチレン：日本ポリエチレン株式会社、商品名「ＰＥ１５」
ｄ）アイオノマー樹脂：三井・デュポンポリケミカル株式会社製、商品名「ＥＭＡＡ３０」 In the following Examples 1 and 2 and Comparative Examples 1 and 2, the following materials a) to d) were used.
a) Polyethylene terephthalate: manufactured by Toyobo Co., Ltd., trade name "PET12"
b) Aluminum: Made by UACJ Corporation, product name "AL7"
c) Polyethylene: Japan Polyethylene Corporation, trade name "PE15"
d) Ionomer resin: Mitsui / DuPont Polychemical Co., Ltd., trade name "EMAA30"
ａ）ポリエチレンテレフタレート：東洋紡績株式会社製、商品名「ＰＥＴ１２」
ｂ）アルミニウム：株式会社ＵＡＣＪ製、商品名「ＡＬ７」
ｃ）ポリエチレン：日本ポリエチレン株式会社、商品名「ＰＥ１５」
ｄ）アイオノマー樹脂：三井・デュポンポリケミカル株式会社製、商品名「ＥＭＡＡ３０」 In the following Examples 1 and 2 and Comparative Examples 1 and 2, the following materials a) to d) were used.
a) Polyethylene terephthalate: manufactured by Toyobo Co., Ltd., trade name "PET12"
b) Aluminum: Made by UACJ Corporation, product name "AL7"
c) Polyethylene: Japan Polyethylene Corporation, trade name "PE15"
d) Ionomer resin: Mitsui / DuPont Polychemical Co., Ltd., trade name "EMAA30"
（実施例１）
下記＜第１層＞～＜第３層＞を積層・圧着して積層フィルムを作成した。
＜第１層＞ポリエチレンテレフタレート層（１５μｍ）
＜第２層＞上記第１層上に積層された、上記第１層側からアルミニウム層（８μｍ）およびポリエチレン層（１５μｍ）
＜第３層＞上記第２層上に積層された、ポリプロピレン層（２５μｍ）
上記積層フィルムを＜第１層＞を内側として２つ折りにし、折った内側に上記ＴＣＣＡ含有錠剤を置き、開放状態の三方を熱圧着シームし、シームの外側を切り出し、実施例１のＴＣＣＡ含有錠剤トリクロロイソシアヌル酸錠の包装体を作成した。 (Example 1)
The following <first layer> to <third layer> were laminated and pressure-bonded to prepare a laminated film.
<First layer> Polyethylene terephthalate layer (15 μm)
<Second layer> An aluminum layer (8 μm) and a polyethylene layer (15 μm) laminated on the first layer from the first layer side.
<Third layer> A polypropylene layer (25 μm) laminated on the second layer.
The laminated film is folded in half with the <first layer> on the inside, the TCCA-containing tablet is placed inside the folded film, the three sides in the open state are thermocompression-bonded, and the outside of the seam is cut out to cut out the TCCA-containing tablet of Example 1. A package of trichloroisocyanuric acid tablets was prepared.
下記＜第１層＞～＜第３層＞を積層・圧着して積層フィルムを作成した。
＜第１層＞ポリエチレンテレフタレート層（１５μｍ）
＜第２層＞上記第１層上に積層された、上記第１層側からアルミニウム層（８μｍ）およびポリエチレン層（１５μｍ）
＜第３層＞上記第２層上に積層された、ポリプロピレン層（２５μｍ）
上記積層フィルムを＜第１層＞を内側として２つ折りにし、折った内側に上記ＴＣＣＡ含有錠剤を置き、開放状態の三方を熱圧着シームし、シームの外側を切り出し、実施例１のＴＣＣＡ含有錠剤トリクロロイソシアヌル酸錠の包装体を作成した。 (Example 1)
The following <first layer> to <third layer> were laminated and pressure-bonded to prepare a laminated film.
<First layer> Polyethylene terephthalate layer (15 μm)
<Second layer> An aluminum layer (8 μm) and a polyethylene layer (15 μm) laminated on the first layer from the first layer side.
<Third layer> A polypropylene layer (25 μm) laminated on the second layer.
The laminated film is folded in half with the <first layer> on the inside, the TCCA-containing tablet is placed inside the folded film, the three sides in the open state are thermocompression-bonded, and the outside of the seam is cut out to cut out the TCCA-containing tablet of Example 1. A package of trichloroisocyanuric acid tablets was prepared.
（比較例１）
下記＜第１層＞～＜第３層＞を積層・圧着して積層フィルムを作成した。
＜第１層＞ポリエチレンテレフタレート層（１５μｍ）
＜第２層＞上記第１層上に積層された、上記第１層側からアルミニウム層（７μｍ）およびポリエチレンテレフタレート層（１５μｍ）
＜第３層＞上記第２層上に積層された、上記第２層上に積層された、ポリプロピレン層（２５μｍ）
上記積層フィルムを＜第１層＞を内側として２つ折りにし、折った内側に上記ＴＣＣＡ含有錠剤を置き、開放状態の三方を熱圧着シームし、シームの外側を切り出し、比較例１のＴＣＣＡ含有錠剤トリクロロイソシアヌル酸錠の包装体を作成した。 (Comparative Example 1)
The following <first layer> to <third layer> were laminated and pressure-bonded to prepare a laminated film.
<First layer> Polyethylene terephthalate layer (15 μm)
<Second layer> An aluminum layer (7 μm) and a polyethylene terephthalate layer (15 μm) laminated on the first layer from the first layer side.
<Third layer> A polypropylene layer (25 μm) laminated on the second layer and laminated on the second layer.
The laminated film is folded in half with the <first layer> on the inside, the TCCA-containing tablet is placed inside the folded film, the three sides in the open state are thermocompression-bonded, and the outside of the seam is cut out to cut out the TCCA-containing tablet of Comparative Example 1. A package of trichloroisocyanuric acid tablets was prepared.
下記＜第１層＞～＜第３層＞を積層・圧着して積層フィルムを作成した。
＜第１層＞ポリエチレンテレフタレート層（１５μｍ）
＜第２層＞上記第１層上に積層された、上記第１層側からアルミニウム層（７μｍ）およびポリエチレンテレフタレート層（１５μｍ）
＜第３層＞上記第２層上に積層された、上記第２層上に積層された、ポリプロピレン層（２５μｍ）
上記積層フィルムを＜第１層＞を内側として２つ折りにし、折った内側に上記ＴＣＣＡ含有錠剤を置き、開放状態の三方を熱圧着シームし、シームの外側を切り出し、比較例１のＴＣＣＡ含有錠剤トリクロロイソシアヌル酸錠の包装体を作成した。 (Comparative Example 1)
The following <first layer> to <third layer> were laminated and pressure-bonded to prepare a laminated film.
<First layer> Polyethylene terephthalate layer (15 μm)
<Second layer> An aluminum layer (7 μm) and a polyethylene terephthalate layer (15 μm) laminated on the first layer from the first layer side.
<Third layer> A polypropylene layer (25 μm) laminated on the second layer and laminated on the second layer.
The laminated film is folded in half with the <first layer> on the inside, the TCCA-containing tablet is placed inside the folded film, the three sides in the open state are thermocompression-bonded, and the outside of the seam is cut out to cut out the TCCA-containing tablet of Comparative Example 1. A package of trichloroisocyanuric acid tablets was prepared.
（比較例２）
下記＜第１層＞～＜第２層＞を積層・圧着して積層フィルムを作成した。
＜第１層＞最下層側からアルミニウム層（７μｍ）およびポリエチレン層（１５μｍ）
＜第２層＞ポリエチレンテレフタレート層（１２μｍ）
上記積層フィルムを＜第１層＞を内側として２つ折りにし、折った内側に上記ＴＣＣＡ含有錠剤を置き、開放状態の三方を熱圧着シームし、シームの外側を切り出し、比較例２のＴＣＣＡ含有錠剤トリクロロイソシアヌル酸錠の包装体を作成した。 (Comparative Example 2)
The following <first layer> to <second layer> were laminated and pressure-bonded to prepare a laminated film.
<First layer> Aluminum layer (7 μm) and polyethylene layer (15 μm) from the bottom layer side
<Second layer> Polyethylene terephthalate layer (12 μm)
The laminated film is folded in half with the <first layer> on the inside, the TCCA-containing tablet is placed inside the folded film, the three sides in the open state are thermocompression-bonded, and the outside of the seam is cut out to cut out the TCCA-containing tablet of Comparative Example 2. A package of trichloroisocyanuric acid tablets was prepared.
下記＜第１層＞～＜第２層＞を積層・圧着して積層フィルムを作成した。
＜第１層＞最下層側からアルミニウム層（７μｍ）およびポリエチレン層（１５μｍ）
＜第２層＞ポリエチレンテレフタレート層（１２μｍ）
上記積層フィルムを＜第１層＞を内側として２つ折りにし、折った内側に上記ＴＣＣＡ含有錠剤を置き、開放状態の三方を熱圧着シームし、シームの外側を切り出し、比較例２のＴＣＣＡ含有錠剤トリクロロイソシアヌル酸錠の包装体を作成した。 (Comparative Example 2)
The following <first layer> to <second layer> were laminated and pressure-bonded to prepare a laminated film.
<First layer> Aluminum layer (7 μm) and polyethylene layer (15 μm) from the bottom layer side
<Second layer> Polyethylene terephthalate layer (12 μm)
The laminated film is folded in half with the <first layer> on the inside, the TCCA-containing tablet is placed inside the folded film, the three sides in the open state are thermocompression-bonded, and the outside of the seam is cut out to cut out the TCCA-containing tablet of Comparative Example 2. A package of trichloroisocyanuric acid tablets was prepared.
（実施例２）
実施例１の包装体において、＜第３層＞のポリプロピレン層（２５μｍ）を、アイオノマー樹脂で形成した層（３０μｍ）に変更した以外は実施例１と同様にして、実施例２のＴＣＣＡ含有錠剤の包装体を作成した。 (Example 2)
In the packaging of Example 1, the TCCA-containing tablet of Example 2 was the same as in Example 1 except that the polypropylene layer (25 μm) of the <third layer> was changed to a layer (30 μm) formed of an ionomer resin. Ionomer packaging was created.
実施例１の包装体において、＜第３層＞のポリプロピレン層（２５μｍ）を、アイオノマー樹脂で形成した層（３０μｍ）に変更した以外は実施例１と同様にして、実施例２のＴＣＣＡ含有錠剤の包装体を作成した。 (Example 2)
In the packaging of Example 1, the TCCA-containing tablet of Example 2 was the same as in Example 1 except that the polypropylene layer (25 μm) of the <third layer> was changed to a layer (30 μm) formed of an ionomer resin. Ionomer packaging was created.
＜安定性試験＞
上記実施例１～２・比較例１～２で作成したＴＣＣＡ含有錠剤の包装体を、４０℃、湿度６０％で３ヶ月保存試験を行った。その結果を下記［表２］に整理して示す。 <Stability test>
The packaging of TCCA-containing tablets prepared in Examples 1 and 2 and Comparative Examples 1 and 2 was stored at 40 ° C. and 60% humidity for 3 months. The results are organized and shown in [Table 2] below.
上記実施例１～２・比較例１～２で作成したＴＣＣＡ含有錠剤の包装体を、４０℃、湿度６０％で３ヶ月保存試験を行った。その結果を下記［表２］に整理して示す。 <Stability test>
The packaging of TCCA-containing tablets prepared in Examples 1 and 2 and Comparative Examples 1 and 2 was stored at 40 ° C. and 60% humidity for 3 months. The results are organized and shown in [Table 2] below.
また、上記＜安定性試験＞で安定と判定された実施例１および実施例２のＴＣＣＡ含有錠剤を５Ｌの水道水で溶解させたところ、直ちに溶解し、ｐＨは６．５であった。また、次亜塩素酸の濃度は２００ｐｐｍであった。
Further, when the TCCA-containing tablets of Example 1 and Example 2 judged to be stable in the above <stability test> were dissolved in 5 L of tap water, they were immediately dissolved and the pH was 6.5. The concentration of hypochlorous acid was 200 ppm.
このように、本件発明のＴＣＣＡ含有錠剤の包装体により、ＴＣＣＡ含有錠剤の保存・保管期間において、ＴＣＣＡ含有錠剤の分解を大幅に低減することができ、いつでも、どこでも安定して所定の濃度の非電離型次亜塩素酸が得られることがわかる。
As described above, the packaging of the TCCA-containing tablet of the present invention can significantly reduce the decomposition of the TCCA-containing tablet during the storage and storage period of the TCCA-containing tablet, and can stably reduce the decomposition of the TCCA-containing tablet at a predetermined concentration anytime and anywhere. It can be seen that ionized hypochlorous acid can be obtained.
１ 第１層
１－１ ポリエチレンテレフタレート層
２ 第２層
２－１ ポリエチレン層
２－２ 金属層
３ 第３層
３－１ 弾性樹脂層
４ 積層フィルム
５ トリクロロイソシアヌル酸を含有する錠剤（ＴＣＣＡ含有錠剤）
Ａ 溶着部分 1 1st layer 1-1Polyethylene terephthalate layer 2 2nd layer 2-1 Polyethylene layer 2-2 Metal layer 3 3rd layer 3-1 Elastic resin layer 4 Laminated film 5 Tablets containing trichloroisocyanuric acid (TCCA-containing tablets)
A Welded part
１－１ ポリエチレンテレフタレート層
２ 第２層
２－１ ポリエチレン層
２－２ 金属層
３ 第３層
３－１ 弾性樹脂層
４ 積層フィルム
５ トリクロロイソシアヌル酸を含有する錠剤（ＴＣＣＡ含有錠剤）
Ａ 溶着部分 1 1st layer 1-1
A Welded part
Claims (9)
- トリクロロイソシアヌル酸を含有する錠剤が、
ａ）ポリエチレンテレフタレート層からなる第１層、
ｂ）上記第１層上に積層された、上記第１層側から金属層およびポリエチレン層を配した第２層、および
ｃ）上記第２層上に積層された、弾性樹脂層からなる第３層
を有する２枚の積層フィルムにより、上記第１層が対面するようにして挟持され、
上記２枚の積層フィルム同士の溶着により密封されてなる、トリクロロイソシアヌル酸を含有する錠剤の包装体。 Tablets containing trichloroisocyanuric acid
a) A first layer composed of a polyethylene terephthalate layer,
b) A third layer composed of an elastic resin layer laminated on the first layer, a second layer in which a metal layer and a polyethylene layer are arranged from the first layer side, and c) a second layer laminated on the second layer. The first layer is sandwiched by two laminated films having layers so as to face each other.
A package of tablets containing trichloroisocyanuric acid, which is sealed by welding the two laminated films to each other. - 上記錠剤が複数個存在し、該複数個の錠剤が、上記２枚の積層フィルムの溶着によりそれぞれ個別に密封されてなることを特徴とする、請求項１に記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The tablet containing trichloroisocyanuric acid according to claim 1, wherein a plurality of the above tablets are present, and the plurality of tablets are individually sealed by welding the two laminated films. Packaging.
- 上記錠剤が、さらに無水硫酸ナトリウムを含有することを特徴とする、請求項１または２に記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The package of a tablet containing trichloroisocyanuric acid according to claim 1 or 2, wherein the tablet further contains anhydrous sodium sulfate.
- 上記錠剤が、更にアルカリ金属の炭酸塩および／または炭酸水素塩を含有する請求項１～３のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The package of a tablet containing trichloroisocyanuric acid according to any one of claims 1 to 3, wherein the tablet further contains an alkali metal carbonate and / or a hydrogen carbonate.
- 上記第１層の上記ポリエチレンテレフタレート層の厚さが５～２５μｍであることを特徴とする、請求項１～４のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The package of a tablet containing trichloroisocyanuric acid according to any one of claims 1 to 4, wherein the polyethylene terephthalate layer of the first layer has a thickness of 5 to 25 μm.
- 上記第２層の上記金属層の厚さが１～２０μｍであり、上記ポリエチレン層の厚さが１０～２０μｍであることを特徴とする、請求項１～５のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The trichloroisocyanuric acid according to any one of claims 1 to 5, wherein the thickness of the metal layer of the second layer is 1 to 20 μm, and the thickness of the polyethylene layer is 10 to 20 μm. Package of tablets containing.
- 上記金属層がアルミニウム層であることを特徴とする、請求項１～６のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The package of a tablet containing trichloroisocyanuric acid according to any one of claims 1 to 6, wherein the metal layer is an aluminum layer.
- 上記第３層の上記弾性樹脂層を形成する樹脂が、ポリプロピレン、アクリル系樹脂またはアイオノマー樹脂のいずれかであることを特徴とする、請求項１～７のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The trichloroisocyanuric acid according to any one of claims 1 to 7, wherein the resin forming the elastic resin layer of the third layer is either polypropylene, acrylic resin or ionomer resin. Package of tablets to be used.
- 上記第３層の上記弾性樹脂層の厚さが２０～５０μｍであることを特徴とする、請求項１～８のいずれかに記載のトリクロロイソシアヌル酸を含有する錠剤の包装体。 The package of a tablet containing trichloroisocyanuric acid according to any one of claims 1 to 8, wherein the elastic resin layer of the third layer has a thickness of 20 to 50 μm.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019174754 | 2019-09-06 | ||
| JP2019-174754 | 2019-09-06 | ||
| JP2020-147577 | 2020-09-02 | ||
| JP2020147577A JP2021041162A (en) | 2019-09-06 | 2020-09-02 | Package of tablet containing trichloroisocyanuric acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021045237A1 true WO2021045237A1 (en) | 2021-03-11 |
Family
ID=74852367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2020/033842 WO2021045237A1 (en) | 2019-09-06 | 2020-09-07 | Packaging body for tablet containing trichloroisocyanuric acid |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2021045237A1 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5762271A (en) * | 1980-10-03 | 1982-04-15 | Nissan Chem Ind Ltd | Storing method of chlorinated isocyanuric acid or salt thereof |
| JPH0653464U (en) * | 1992-12-28 | 1994-07-22 | 恵徳株式会社 | Enclosed bag for tablets |
| JPH08151069A (en) * | 1994-11-29 | 1996-06-11 | Idemitsu Petrochem Co Ltd | Package |
| JPH10212209A (en) * | 1997-01-30 | 1998-08-11 | Johnson Co Ltd | Sterilizing cleaning agent |
| JP2002119575A (en) * | 2000-10-16 | 2002-04-23 | Pigeon Corp | Halogen gas releasing drug packaging bag and packaging halogen gas releasing drug |
| JP2006010924A (en) * | 2004-06-24 | 2006-01-12 | Konica Minolta Photo Imaging Inc | Solid processing agent for processing silver halide color photographic sensitive material and processing method for silver halide color photographic sensitive material using same |
| US20110103720A1 (en) * | 2008-05-29 | 2011-05-05 | Hydrus B.V. | Method of manufacturing a bag and a bag |
| JP2017081113A (en) * | 2015-10-30 | 2017-05-18 | 藤森工業株式会社 | Laminated body for packaging bag and method for producing the same, packaging bag and method for producing the same |
-
2020
- 2020-09-07 WO PCT/JP2020/033842 patent/WO2021045237A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5762271A (en) * | 1980-10-03 | 1982-04-15 | Nissan Chem Ind Ltd | Storing method of chlorinated isocyanuric acid or salt thereof |
| JPH0653464U (en) * | 1992-12-28 | 1994-07-22 | 恵徳株式会社 | Enclosed bag for tablets |
| JPH08151069A (en) * | 1994-11-29 | 1996-06-11 | Idemitsu Petrochem Co Ltd | Package |
| JPH10212209A (en) * | 1997-01-30 | 1998-08-11 | Johnson Co Ltd | Sterilizing cleaning agent |
| JP2002119575A (en) * | 2000-10-16 | 2002-04-23 | Pigeon Corp | Halogen gas releasing drug packaging bag and packaging halogen gas releasing drug |
| JP2006010924A (en) * | 2004-06-24 | 2006-01-12 | Konica Minolta Photo Imaging Inc | Solid processing agent for processing silver halide color photographic sensitive material and processing method for silver halide color photographic sensitive material using same |
| US20110103720A1 (en) * | 2008-05-29 | 2011-05-05 | Hydrus B.V. | Method of manufacturing a bag and a bag |
| JP2017081113A (en) * | 2015-10-30 | 2017-05-18 | 藤森工業株式会社 | Laminated body for packaging bag and method for producing the same, packaging bag and method for producing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2130794B1 (en) | Pure chlorine dioxide solution, and gel-like composition and foamable composition each comprising the same | |
| US8262929B2 (en) | Massive bodies containing free halogen source for producing highly converted solutions of chlorine dioxide | |
| US11772968B2 (en) | Multi-chamber hypochlorous acid dispenser | |
| USRE36064E (en) | Disinfection method and composition therefor | |
| US5185161A (en) | Disinfection method and composition therefor | |
| EP3094177B1 (en) | Sporocidal disinfectant or sanitising composition | |
| KR20190084395A (en) | Sustained release formulation for chorine dioxide generation and chorine dioxide generation package using the same that | |
| WO2005037327A2 (en) | Chlorine dioxide gel and associated methods | |
| JP2012036072A (en) | Product shape and component composition of chlorine dioxide generator at using time | |
| CN106900707A (en) | A kind of antiseptic sterilization agent containing peroxide | |
| GB2437489A (en) | Disinfectant mixture of a donor of freely available chlorine (e.g. hypochlorite) and a buffering agent or acid, optionally in the form of an aqueous solution | |
| WO2021045237A1 (en) | Packaging body for tablet containing trichloroisocyanuric acid | |
| CN101143225B (en) | Air purifying agent and its preparing process | |
| JP2021041162A (en) | Package of tablet containing trichloroisocyanuric acid | |
| CN106689194A (en) | Sustained-release disinfectant fluid | |
| KR20220012774A (en) | Solid type composition for releasing chlorine dioxide gas and sterilizer/deodorant using the same | |
| JP6550570B2 (en) | Chemical sprayer with solid drug enclosed | |
| JP2019156784A (en) | Tablet for obtaining aqueous hypochlorite, and blister pack article packaging the tablet | |
| WO2005000368A1 (en) | Disinfecting deodorizers, disinfecting deodorizer solutions, and method of disinfecting and deodorizing with the same | |
| US7651628B2 (en) | Compression molded product of effervescent chlorinated isocyanuric acid | |
| CN212127510U (en) | Disinfectant generator capable of controlling chlorine dioxide gas output | |
| WO2020120193A1 (en) | A disinfection system | |
| WO2023214221A1 (en) | Composition and making of self-forming, continuous-release antimicrobial air gel | |
| CN1265710C (en) | Iodate composition and its application in environmental sterilization | |
| JPH0352802A (en) | Alcohol formulation containing chlorine dioxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20860050 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20860050 Country of ref document: EP Kind code of ref document: A1 |